```
625668
5 MR" 7 10 92
Set
         Items
                 Description
S1
        26174
                 SOMATOTROPIN
SP
        46607
                 GROWTH () HORMONE
S3
        57585
                 S1 OR S2
S4
        118932
                 MUTATION
S5
                 S3 AND S4
           266
S6
        22392
                 HELIX
S7
            6
                 S5 AND S6
SB
             3
                 AU="LEBENS M R" OR AU="LEBENS MR"
S9
             1
                 AU="TARDY D"
          1000
                 AU="FISCHER M"
S10
S11
             171
                 S3 AND S10
          1230
512
                 E3-E37
                 S3 AND S12
513
             ıΖı
S14
             121
                 S1 AND S12
S15
        19693
                 TUMOR() NECROSIS() FACTOR
S16
       299981
                 SEQUENCE
S17
          839
                 S15 AND S16
S18
          617
                 RD (unique items)
S19
       342669
                 RECEPTOR
S20
         1994
                 S15 AND S19
S21
       110839/
                 SOLUBLE
S22
          233
                 S20 AND S21
S23
           151
                 RD (unique items)
S24
           12
                 SEUENCE
S25
       299981
                 SEQUENCE
S26
            14
                 S23 AND S25
?t s26/3/1-14
```

```
26/3/1 (Item 1 from file: 155)
```

Ø8Ø72529 9221Ø529

Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding.

Marsters SA; Frutkin AD; Simpson NJ; Fendly BM; Ashkenazi A

Department of Immunobiology, Genentech, Inc., South San Francisco, California 94080.

J Biol Chem (UNITED STATES) Mar 25 1992, 267 (9) p5747-50, ISSN 0021-9258 Journal Code: HIV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

26/3/2 (Item 2 from file: 155)

08054029 92192029

Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor.

Brakebusch C; Nophar Y; Kemper O; Engelmann H; Wallach D

Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel.

EMBO J (ENGLAND) Mar 1992, 11 (3) p943-50, ISSN 0261-4189

Journal Code: EMB

Languages: ENGLISH

Document type: JOURNAL ARTICLE

26/3/3 (Item 3 from file: 155) Ø7997196 92135196

Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation.

Rennica D; Kohr WJ; Fendly BM; Shire SJ; Raab HE; Borchardt PE; Lewis M; Goeddel DV

Department of Molecular Biology, Genentech, Inc., South San Francisco,

```
198008
 Ket
        Items Index-term
 E1
            6
              AU=WALLACH C B
              AU=WALLACH CB
 EЗ
          371 *AU=WALLACH D
 E4
           1 AU=WALLACH D E
 E5
              AU=WALLACH D F
 E6
              AU=WALLACH D F H
          188
 E7
              AU=WALLACH D H
 E8
               AU=WALLACH D H F
 E9
               AU=WALLACH D P
 E10
               AU=WALLACH DE
 E11
          155 AU-WALLACH DF
 E12
            2 AU=WALLACH DFH
           Enter P or E for more
      530
              371 AU="WALL Y D"
 ?s s15 and s30
             19893 8.5
              371 930
      S31
               88 S15 AND
 ?s s20 amd s30
             1994 520
              371
                   530
      532
              -33 S20 AND S30
?t s32/3/1-33
 32/3/1
             (Item 1 from file: 155)
08130484
           92268484
  Selective decrease in cell surface expression and mRNA level of the
55-kDa tumor necrosis factor receptor during differentiation of HL-60 cells
into macrophage-like but not granulocyte-like cells.
  Winzen R; Wallach D; Engelmann H; Nophar Y; Brakebusch C; Kemper O; Resch
K; Holtmann H
  Institute of Molecular Pharmacology, Medical School, Hannover, FRG.
J Immunol (UNITED STATES) Jun 1 1992, 148 (11) p3454-60,
0022-1767
           Journal Code: IFB
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE
            (Item 2 from file: 155)
 32/3/2
28054029
          92192029
 Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor
abolishes signalling, but not induced shedding of the receptor.
 Brakebusch C; Nophar Y; Kemper O; Engelmann H; Wallach D
 Department of Molecular Genetics and Virology, Weizmann Institute of
Science, Rehovot, Israel.
 EMBO Ĵ (ENGLANĎ) Mar 1992, 11 (3) p943-50, ISSN 0261-4189
Journal Code: EMB
 Languages: ENGLISH
Document type: JOURNAL ARTICLE
32/3/3
            (Item 3 from file: 155)
18004967
          92142967
 Soluble and cell surface receptors for tumor necrosis factor.
 Wallach D; Engelmann H; Nophar Y; Aderka D; Kemper O; Hornik V; Holtmann
l; Brakebusch C
 Department of Molecular Genetics and Virology, Weizmann Institute of
cience, Rehovot, Israel.
 Agents Actions Suppl (SWITZERLAND)
                                         1991, 35 p51-7, ISSN 0379-0363
ournal Code: 2YH
 Languages: ENGLISH
 Document type: JOURNAL ARTICLE; REVIEW; REVIEW LITERATURE
3073/4
           (Item 4 from file: 155)
         92121813
7983813
Stabilization of the bioactivity of tumor necrosis factor by its soluble
eceptors.
Aderka D; Engelmann H; Maor Y; Brakebusch C; Wallach D
Department of Medicine T, Tel-Aviv Medical Center, Sackler Faculty of edicine, Tel-Aviv University, Israel.
 U Exp Med (UNITED STATES)
                              Feb 1 1992, 175 (2) p323-9, ISSN 0022-1007
Jurnal Code: I2V
Languages: ENGLISH
Document type: JOURNAL ARTICLE
32/3/5
           (Item 5 from file: 155)
4873651
         92011651
Human neutrophil elastase releases a ligand-binding fragment from the
j-kDa tumor necrosis factor (TNF) receptor. Comparison with the oteolytic activity responsible for shedding of TNF receptors from
```

imulated neutrophils.

CELL SURFACE AND SOLUBLE TNF RECEPTORS

WALLACH D; ADERKA D; ENGELMANN H; NOPHAR Y; KEMPER O; HOLTMANN H;

BRAKEBUSCH C; VILLA S; GONDI F G; BUCCIARELLI U

DEP. MOL. GENET. VIROL., WEIZMANN INST. SCI., REHOVOT 76100, ISR.

OSAWA, T. AND B. BONAVIDA (ED.). TUMOR NECROSIS FACTOR:

STRUCTURE-FUNCTION RELATIONSHIP AND CLINICAL APPLICATION; 3RD INTERNATIONAL

CONFERENCE ON TUMOR NECROSIS FACTOR AND RELATED CYTOKINES, MAKUHARI, JAPAN,

NOVEMBER 21-25, 1990. IX+291P. S. KARGER AG: BASEL, SWITZERLAND; NEW YORK,

NEW YORK, USA. ILLUS. ISBN 3-8055-5458-3. 0 (0). 1992. 47-57. CODEN:

36660

Language: ENGLISH

Document Type: CONFERENCE PAPER

?e au=aggaæwal

nontual code: His Languages: ENGLISH Document type: JOURNAL TICLE (Item 9 from file: 155) 26/3/9 07526991 91045991 A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Kohno T; Brewer MT; Baker SL; Schwartz PE; King MW; Hale KK; Squires CH; Thompson RC; Vannice JL Synergen, Inc., Boulder, CO 80301. Proc Natl Acad Sci U S A Nov 1990, 87 (21) p8331-5, ISSN 0027-8424 Journal Code: PV3 Languages: ENGLISH Document type: JOURNAL ARTICLE 26/3/10 (Item 10 from file: 155) @7498**5**@9 91@175@9 Clóning of human tumor necrosis factor (TNF) receptor cDNA and expression of ∱ecombinant soluble TNF-binding protein. Gray PW; Barrett K; Chantry D; Turner M; Feldmann M Charing Cross Sunley Research Centre, Hammersmith, London, England. Proc Natl Acad Sci U S A Oct 1990, 87 (19) p7380-4, ISSN 0027-8424 Journal Code: PV3 Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 11 from file: 155) 26/3/11 07487021 91006021 Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. Nophar Y; Kemper O; Brakebusch C; Englemann H; Zwang R; Aderka D; Holtmann H; Wallach D Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel. Oct 1990, 9 (10) p3269-78, ISSN 0261-4189 Journal Code: EMB Languages: ENGLISH Document type: JOURNAL ARTICLE 26/3/12 (Item 12 from file: 155) 07328285 90235285 Molecular cloning and expression of a receptor for human tumor necrosis factor. Schall TJ; Lewis M; Koller KJ; Lee A; Rice GC; Wong GH; Gatanaga T; 🕟 Granger GA; Lentz R; Raab H; et al Department of Molecular Biology, Genentech, Inc., South San Francisco, California 94080. Apr 20 1990, 61 (2) p361-70, ISSN 0092-8674 Journal Code: CQ4 Languages: ENGLISH Document type: JOURNAL ARTICLE 26//3/13 (Item 13 from file: 155) 0|7*]*203215 90110215 Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. Engelmann H; Novick D; Wallach D Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel. J Biol Chem Jan 25 1990, 265 (3) p1531-6, ISSN 0021-9258 Journal Code: HIV Languages: ENGLISH Document type: JOURNAL ARTICLE

26/3/14

(Item 1 from file: 5)

water of the samples Biochemistry (UNITED STATES) Feb 1992, 31 (4) p1134-41. 0006-2960 Journal Code: A0G Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 4 from file: 155) 26/3/4 07966250 92104250 Functional significance of human vascular smooth muscle cell-derived interleukin 1 in paracrine and autocrine regulation pathways. Loppnow H; Libby P Department of Biochemistry, Forschungsinstitut Borstel, Germany. Res (UNITED STATES) Feb 1992, 198 (2) p283-90, ISSN 0014-4827 Journal Code: EPB Contract/Grant No.: HL34636 Languages: ENGLISH Document type: JOURNAL ARTICLE 26/N3/5 (Item 5 from file: 155) 92078859 Ø/7/940859 /A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. Peppel K; Crawford D; Beutler B Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75235. J Exp Med (UNITED STATES) Dec 1 1991, 174 (6) p1483-9, ISSN 0022-1007 Journal Code: I2V Contract/Grant No.: PO1-DK42582-01 Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 6 from file: 155) 26/3/6 07688415 91207415 T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Smith CA; Davis T; Wignall JM; Din WS; Farrah T; Upton C; McFadden G; Goodwin RG Immunex Corporation, Seattle, WA 98101. Biophys Res Commun Apr 15 1991, 176 (1) p335-42. ISSN Journal Code: 9Y8 0006-291X Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 7 from file: 155) 26/3/7 07571841 91090841 Molecular cloning and expression of human and rat tumor necrosis factor and its soluble derivative, נושה necrosis receptor chain (p6Ø) factor-binding protein. Himmler A; Maurer-Fogy I; Kronke M; Scheurich P; Pfizenmaier K; Lantz M; Olsson I; Hauptmann R; Stratowa C; Adolf GR Ernst Boehringer Institut, Bender + Co GesmbH, V/enna, Austria. Dec 1990, 9 (10) p705-15, ISSN 2044-5498 DNA Cell Biol Journal Code: AF9 Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 8 from file: 155) 26/3/8 07543364 / 91062364 Purification and characterization of an inhibitor (soluble tumor necrosis factor/ receptor) for tumor necrosis factor and lymphotoxin obtained from the gerum ultrafiltrates of human cancer patients. VGátanaga T; Hwang CD; Kohr W; Cappuccini F; Lucci JA 3d; Jeffes EW; Lentz R; Tomich J; Yamamoto RS; Granger GA Molecar Biology and Biochestry, University of Department of California, Irvine 92717. Proc Natl Acad Sci U S A Nov 1990, 87 (22) p8781-4, ISSN 0027-8424

```
(FILE 'USPAT' ENTERED AT 10:58:14 ON 10 JUL 92)
                         DEL HIS
  L1
                    254 S TUMOR NECROSIS FACTOR
  L2
                201937 S SEQUENCE
  L3
                    116 S L1 AND L2
  => d 13 cit 400-116
  100. 4,785,077, Nov. 15, 1988, Substantially pure cytotoxicity
  triggering factor; Richard Kornbluth, et al., 530/351; 424/85.1, 85.4; 435/70.3, 70.4, 240.31, 948; 530/350, 827
## 101. 4,777,242, Oct. 11, 1988, Purification of recombinant **tumor**

**necrosis** **factor**; Lynn P. Nelles, 530/351; 435/69.5, 603; 530/412,
 102. 4,770,995, Sep. 13, 1988, Detection of the sensitivity of cells to the effects of **tumor** necrosis** **factor** and imphotoxin; Berish Y. Rubin, et al., 435/7.25, 436/501, 544, 545, 546
 188. 5,752,585, Jun. 21, 1988, Oxidation-resistant muteins; Kirston E. Koths, et al., 435/252.33, 172.3, 252.3, 256, 320.1; 530/351; 536/27; 930/141, 142; 935/10, 111
 104. 4,748,234, May 31, 1988, Process for recovering reffactors
 containing heterologous proteins from microbial hosts; Glenn Dorin, et al., 530/412; 435/69.51, 69.52; 530/351, 414, 416, 417, 422, 424, 6829
 105. 4,721,671, Jan. 26, 1988, Efficient prokaryotic expression system
 using portions of the E. coli .beta.; Algis Anilionis, et al., 435/69.7, 172.3, 201, 252.33, 320.1, 849; 530/350; 536/27; 930/10, 240; 935/14
 [IMAGE AVAILABLE]
 106. 4,684,623, Aug. 4, 1987, Use of **tumor** **necrosis** **factor**
 as a weight regulator; James W. Larrick, et al., 514/12; 424/85.1, 85.8;
 514/11, 13, 14; 530/389.2; 930/144
 107. 4,677,197, Jun. 30, 1987, Purification method for **tumor**
 **necrosis** **factor**; Leo S. Lin, et al., 530/417, 351, 416; 930/144,
 DIG. 530
 108. 4,677,064, Jun. 30, 1987, Human **tumor** **necrosis** **factor**; David F. Mark, et al., 435/69.1; 424/85.1, 88; 435/172.3, 252.3, 320.1; 514/8; 530/350, 351, 395, 808; 536/27; 930/144
149. 4,677,063, Jun. 30, 1987, Human **tumor** **necrosis** **factor**; David F. Mark, et al., 435/69.5; 424/85.1, 88; 435/172.3, 240.2, 252.3, 252.33, 320.1; 514/8, 12; 530/350, 351, 395, 808; 536/27; 930/144
 110. 4,656,132, Apr. 7, 1987, Method of improving the yield of
heterologous protein produced by cultivating recombinant bacteria; Arie
Ben-Bassat, et al., 435/69.5, 69.51, 69.52, 172.3; 935/33, 38, 111

    111. 4,650,674, Mar. 17, 1987, Synergistic cytotoxic composition; Bharat
    B. Aggarwal, et al., 424/85.5, 85.4; 435/69.5; 514/12; 930/143, 144

        4,588,585, May 13, 1986, Human recombinant cysteine depleted
 interferon-.beta. muteins; David F. Mark, et al., 424/85.2, 85.6;
 435/69.51, 172.3; 530/351; 930/141, 142
 113. 4,530,787, Jul. 23, 1985, Controlled oxidation of microbially
produced cysteine-containing proteins; Ze'ev Shaked, et al., 530/351; 424/85.2, 85.4, 85.6, 88; 435/69.51, 811; 530/345, 363, 410, 808, 820,
114. 4,529,594, Jul. 16, 1985, Protein having antitumor activity; Hiroshi Hayashi, et al., 514/12; 424/85.1, 88; 530/324, 350, 413, 825,
828, 830; 930/10
        4,518,584, May 21, 1985, Human recombinant interleukin-2 muteins;
David F. Mark, et al., 424/85.2, 85.1, 85.6; 435/69.51, 69.52, 172.3; 514/2, 8, 12; 530/351, 809; 930/141, 142
116. 4,481,137, Nov. 6, 1984, Glycoproteins and processes for their production; Haruo Ohnishi, et al., 530/395; 424/85.1; 435/70.3, 70.4; 514/8, 908; 530/322, 351, 806, 809, 828, 829
=) s receptord his
        (FILE 'USPAT' ENTERED AT 10:58:14 ON 10 JUL 92)
                       DEL HIS
                  254 S TUMOR NECROSIS FACTOR
              201937 S SEQUENCE
                 116 S LI AND LE
```

11032 S RECEPTOR 82 S L1 AND L4

Porteu F; Arockhaus M; wallach D; Engelmann H; Nathan Ur Beatrice and Samuel A. Seaver Laboratory, Department of Medicine, Cornell University Medical College, New York, New York 10021. J Biol Chem Oct 5 1991, 266 (28) p18846-53, ISSN 0021-9258 Journal Code: HIV Contract/Grant No.: CA45218 Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 6 from file: 155) 32/3/6 Ø7871844 92009844 The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p36.3. Kemper O; Derre J; Cherif D; Engelmann H; Wallach D; Berger R Department of Molecular Genetics and Virology, Weitzmann Institute of Science, Rehovot, Israel. Sep 1991, 87 (5) p623-4, ISSN 0340-6717 Journal Code: GED Hum Genet Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 7 from file: 155) 32/3/7 Ø7867499 92ØØ5499 Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Aderka D; Englemann H; Hornik V; Skornick Y; Levo Y; Wallach D; Kushtai G Department of Medicine, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Israel. Cancer Res Oct 15 1991, 51 (20) p5602-7, ISSN 0008-5472 Journal Code: CNF Languages: ENGLISH Document type: JOURNAL ARTICLE 32/3/8 (Item 8 from file: 155) 07774800 91293800 The gene for the type 1 tumor necrosis factor receptor (TNF-R1) is localized on band 12p13. Derre J; Kemper O; Cherif D; Nophar Y; Berger R; Wallach D INSERM U301, Institut de Genetique Moleculaire, Paris, France. Jun 1991, 87 (2) p231-3, ISSN 0340-6717 Journal Code: GED Hum Genet Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 9 from file: 155) 32/3/9 07766027 91285027 Induction of hyporesponsiveness to an early post-binding effect of tumor necrosis factor by tumor necrosis factor itself and interleukin 1. Konig M; Wallach D; Resch K; Holtmann H Institute of Molecular Pharmacology, Medical School, Hannover, FRG. Jul 1991, 21 (7) p1741-5, ISSN 0014-2980 Eur J Immunol Journal Code: EN5 Languages: ENGLISH Document type: JOURNAL ARTICLE 32/3/10 (Item 10 from file: 155) 07762541 91281541 Mechanisms controlling the level of receptors for tumor necrosis factor. Holtmann H; Brakebusch C; Konig M; Klocke R; Winzen R; Resch K; Wallach D Department of Molecular Pharmacology, Medical School Hannover, FRG. Agents Actions Jan 1991, 32 (1-2) p106-8, ISSN 0065-4299 Journal Code: 2XZ Languages: ENGLISH Document type: JOURNAL ARTICLE 32/3/11 (Item 11 from ile: 155)

Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for

07487021

the type i inche, cloned using amino acid sequence data or its soluble form, encodes both the cell surface and a soluble form of the receptor. Nophar Y; Kemper O; __akebusch C; Englemann | | Zwang R; Aderka D; Holtmann H; Wallach D Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel. EMBO J Oct 1990, 9 (10) p3269-78, ISSN 0261-4189 Journal Code: EMB Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 12 from file: 155) 32/3/12 Ø7447443 90354443 Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. Engelmann H; Holtmann H; Brakebusch C; Avni YS; Sarov I; Nophar Y; Hadas E; Leitner O; Wallach D Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel. J Biol Chem Aug 25 1990, 265 (24) p14497-504, ISSN 0021-9258 Journal Code: HIV Languages: ENGLISH Document type: JOURNAL ARTICLE 32/3/13 (Item 13 from file: 155) 07203215 90110215 Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. Engelmann H; Novick D; Wallach D Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel. J Biol Chem Jan 25 1990, 265 (3) p1531-6, ISSN 0021-9258 Journal Code: HIV Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 14 from file: 155) 32/3/14 Ø7ØØ66Ø3 89308603 A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. Engelmann H; Aderka D; Rubinstein M; Rotman D; Wallach D Department of Virology, Weizmann Institute of Science, Rehovot, Israel. J Biol Chem Jul 15 1989, 264 (20) p11974-80, ISSN 0021-9258 Journal Code: HIV Languages: ENGLISH Document type: JOURNAL ARTICLE (Item 15 from file: 155) 32/3/15 Ø6553989 88198989 Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells. Nophar Y; Holtmann H; Ber R; Wallach D Department of Virology, Weizmann Institute of Science, Rehovot, Israel. May 15 1988, 140 (10) p3456-60, ISSN 0022-1767 J Immunol Journal Code: IFB Languages: ENGLISH Document type: JOURNAL ARTICLE 32/3/16 (Item 16 from file: 155) 06307632 87281632 Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. Holtmann H; Wallach D Aug 15 1987, 139 (4) p1161-7, ISSN 0022-1767 J Immunol Journal Code: IFB Languages: ENGLISH

```
LUCHLIZED UN BHND 1836.2-836.3
  KEMPER O; DERRE J; CHERIF D; ENGELMANN H; WALLACH D BERGER R
  UNITE INSERM U. 301, INS GENETIQUE MOLECULAIRE, 2 UE JULIETTE DODU,
F-75010 PARIS, FR.
  HUM GENET 87 (5). 1991. 623-624.
                                    CODEN: HUGED
  Full Journal Title: Human Genetics
  Language: ENGLISH
 32/3/23
             (Item 6 from file: 5)
8599313
            BIOSIS Number: 92064313
  THE GENE FOR THE TYPE 1 TUMOR NECROSIS FACTOR RECEPTOR TNF-R1 IS
LOCALIZED ON BAND 12P13
  DERRE J; KEMPER O; CHERIF D; NOPHAR Y; BERGER R; WALLACH D
  INSERM U301, SDI NO. 15954 CNRS, INST. GENETIQUE MOLECULAIRE, 27 RUE
JULIETTE DODU, F-7510 PARIS, FR.
  HUM GENET 87 (2). 1991. 231-233.
                                      CODEN: HUGED
  Full Journal Title: Human Genetics
 Language: ENGLISH
 32/3/24
             (Item 7 from file: 5)
8445425
            BIOSIS Number: 41129425
  STUDYING STRUCTURE-FUNCTION RELATIONSHIP IN THE HUMAN TYPE 1 P55
TNF-RECEPTOR USING HETEROLOGOUS EXPRESSION IN MURINE CELLS
  BRAKEBUSCH C; NOFHAR Y; KEMPER O; ENGELMANN H; GRUNEWALD M; KING A;
  SCH. MED., HANNOVER, FRG.
  TWENTY-EIGHTH NATIONAL MEETING OF THE SOCIETY FOR LEUKOCYTE BIOLOGY AND
THE TWENTY-FIRST LEUKOCYTE CULTURE CONFERENCE, ASPEN, COLORADO, USA,
SEPTEMBER 28-OCTOBER 1, 1991. J LEUKOCYTE BIOL Ø (SUPPL. 2). 1991. 98.
CODEN: JLBIE
 Language: ENGLISH
 Document Type: CONFERENCE PAPER
             (Item 8 from file: 5)
 32/3/25
7766655
            BIOSIS Number: 90134655
  SOLUBLE FORMS OF TUMOR NECROSIS FACTOR RECEPTORS TNF-RS THE COMPLEMENTARY
DNA FOR THE TYPE I TNF-R CLONED USING AMINO ACID SEQUENCE DATA OF ITS
SOLUBLE FORM ENCODES BOTH THE CELL SURFACE AND A SOLUBLE FORM OF THE
RECEPTOR
  NOPHAR Y; KEMPER O; BRAKEBUSCH C; ENGELMANN H; ZWANG R; ADERKA D;
HOLTMANN H; WALLACH D
  DEF. MOL. GENETICS VIROL., WEIZMANN INST. SCI., REHOVOT, ISRAEL 76100.
  EMBO (EUR MOL BIOL ORGAN) J 9 (10). 1990. 3269-3278. CODEN: EMJOD
 Full Journal Title: EMBO (European Molecular Biology Organization)
Journal
 Language: ENGLISH
32/3/26
             (Item 9 from file: 5)
7743514
            BIOSIS Number: 90111514
  ANTIBODIES TO A SOLUBLE FORM OF A TUMOR NECKOSIS FACTOR THE RECEPTOR HAVE
TNF-LIKE ACTIVITY
  ENGELMANN H; HOLTMANN H; BRAKEBUSCH C; AVNI Y S; SAROV I; NOPHAR Y; HADAS
E; LEITNER O; WALLACH D
  DEF. MOL. GENETICS VIROL., WEIZMANN INST., REHOVOT 76100, ISRAEL.
  J BIOL CHEM 265 (24). 1990. 14497-14504. CODEN: JBCHA
 Full Journal Title: Journal of Biological Chemistry
 Language: ENGLISH
32/3/27
             (Item 10 from file: 5)
           BIOSIS Number: 39061394
7548787
  RECEPTOR-RELATED ASPECTS OF THE MODE OF ACTION OF TUMOR NECROSIS FACTOR
AND ITS MODULATION
 HOLTMANN H; BRAKEBUSCH C; ENGELMANN H; KUENIG M; KLOCKE R; NOPHAR Y;
RESCH K; WALLACH D
  DEP. MOL. PHARMACOL., MEDICAL SCH. HANNOVER, FRG.
  31ST SPRING MEETING OF THE DEUTSCHE GESELLSCHAFT FUER PHARMAKOLOGIE UND
```

```
Document type: JUUKNAL AKIILLE
 32/3/17
             (Item 17 from file: 155)
Ø5948378 86249378
  Binding of human TNF-alpha to high-affinity cell surface receptors:
effect of IFN.
  Israel S; Hahn T; Holtmann H; Wallach D
                Apr 1986, 12 (4) p217-24, ISSN 0165-2478
  Immunol Lett
Journal Code: GIH
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE
 32/3/18
            (Item 1 from file: 5)
8904179
            BIOSIS Number: 42129179
  CELL SURFACE AND SOLUBLE THE RECEPTORS
  WALLACH D; ADERKA D; ENGELMANN H; NOPHAR Y; KEMPER O; HOLTMANN H;
BRAKEBUSCH C; VILLA S; GONDI F G; BUCCIARELLI U
  DEP. MOL. GENET. VIROL., WEIZMANN INST. SCI., REHOVOT 76100, ISR.
  OSAWA, T. AND B. BONAVIDA (ED.). TUMOR NECROSIS FACTOR:
STRUCTURE-FUNCTION RELATIONSHIP AND CLINICAL APPLICATION; 3RD INTERNATIONAL
CONFERENCE ON TUMOR NECROSIS FACTOR AND RELATED CYTOKINES, MAKUHARI, JAPAN,
NOVEMBER 21-25, 1990. IX+291P. S. KARGER AG: BASEL, SWITZERLAND; NEW YORK,
NEW YORK, USA. ILLUS. ISBN 3-8055-5458-3. 0 (0). 1992. 47-57.
36660
 Language: ENGLISH
  Document Type: CONFERENCE PAPER
 32/3/19
            (Item 2 from file: 5)
8897179
            BIOSIS Number: 42122179
  CHANGES IN THE EXPRESSION OF TUMOR NECROSIS FACTOR RECEPTOR DURING
DIFFERENTIATION OF HL-60 CELLS
  HOLTMANN H; WINZEN R; BRAKEBUSCH C; NOPHAR Y; ENGELMANN H; RESCH K;
WALLACH D
  INST. MOLECULAR PHARMACOL., MED. SCH., HANNOVER, FRG.
  KEYSTONE SYMPOSIUM ON CYTOKINES IN GROWTH AND DEVELOPMENT, TAOS, NEW
MEXICO, USA, FEBRUARY 1-8, 1992. J CELL BIOCHEM SUPPL Ø (16 PART B). 1992.
      CODEN: JCBSD
  Language: ENGLISH
  Document Type: CONFERENCE PAPER
 32/3/20
             (Item 3 from file: 5)
8825551
           BIOSIS Number: 42050551
  CONTROL OF THE CELLULAR RESPONSE TO TUMOR NECROSIS FACTOR TNF
  HOLTMANN H; KOENIG M; ENGELMANN H; WALLACH D; RESCH K
  INST. MOL. PHARMACOL., MED. SCH., 3000 HANNOVER 61, GER.
  XXIIND MEETING OF THE SOCIETY OF IMMUNOLOGY, LUEBECK-TRAVEMUENDE,
GERMANY, OCTOBER 23-26, 1991. IMMUNOBIOLOGY 183 (3-4). 1991. 257-258.
CODEN: IMMND
  Language: ENGLISH
  Document Type: CONFERENCE PAPER
             (Item 4 from file: 5)
 32/3/21
            BIOSIS Number: 92132789
8667789
  HUMAN NEUTROPHIL ELASTASE RELEASES A LIGAND-BINDING FRAGMENT FROM THE
75-KDA TUMOR NECROSIS FACTOR THE RECEPTOR COMPARISON WITH THE PROTEOLYTIC
ACTIVITY RESPONSIBLE FOR SHEDDING OF THE RECEPTORS FROM STIMULATED
NEUTROPHILS
  FORTEU F; BROCKHAUS M; WALLACH D; ENGELMANN H; NATHAN C F
  CORNELL UNIV. MED. COLL., BOX 57, 1300 YORK AVE., NEW YORK, N.Y. 10021.
  J BIOL CHEM 266 (28). 1991. 18846-18853.
                                             CODEN: JBCHA
  Full Journal Title: Journal of Biological Chemistry
  Language: ENGLISH
             (Item 5 from le: 5)
 32/3/22
           BIOSIS Number: 2124323
```

THE GENE FOR THE TYPE II P75 TUMOR NECROSIS FACTOR RECEPTOR TNF-RII IS

DIALNET: call cleared by request

Enter Service:

```
IDXIKULUBIE (BERMAN SUCIETY FUR PHARMADULUBY AND TUXICULUGY), MAINZ, WEST
GERMANY, MARCH 13-16, 1990. NAUNYN-SCHMIEDEBERG'S ARCH PHARMACOL 341
(SUPPL.). 1990. R77. CODEN: NSAPC
  Language: ENGLISH
  Document Type: CONFERENCE PAPER
             (Item 41 from file: 5)
 32/3/28
7151362
            BIOSIS Number: 88074107
  A TUMOR NECROSIS FACTOR-BINDING PROTEIN PURIFIED TO HOMOGENEITY FROM
HUMAN URINE PROTECTS CELLS FROM TUMOR NECROSIS FACTOR TOXICITY
  ENGELMANN H; ADERKA D; RUBINSTEIN M; ROTMAN D; WALLACH D
  DEF. VIROL., WEIZMANN INST. SCI., REHOVOT, ISRAEL.
  J BIOL CHEM 264 (20). 1989. 11974-11980. CODEN: JBCHA
  Full Journal Title: Journal of Biological Chemistry
  Language: ENGLISH
 32/3/29
            (Item 12 from file: 5)
6766030
            BIOSIS Number: 36096551
  IL-1 AND 1FN MODULATE TNF-RECEPTOR EXPRESSION IN HUMAN POLYMORPHONUCLEAR
AND MONONUCLEAR LEUKOCYTES
  HAHN T; ENGELMANN H; HOLTMANN H; LANDAU Z; WALLACH D
  PEDIATRIC RES. INST., KAPLAN HOSP., REHOVOT.
  ANNUAL INTERNATIONAL SOCIETY FOR INTERFERON RESEARCH MEETING ON
INTERFERONS AND CYTOKINES, KYOTO, JAPAN, NOVEMBER 14-18, 1988. J INTERFERON
RES 8 (SUPPL. 1). 1988. S148. CODEN: JIRED
  Language: ENGLISH
  Document Type: CONFERENCE PAPER
 32/3/30
            (Item 13 from file: 5)
6562182
            BIOSIS Number: 86028733
  DOMINANCE OF RESISTANCE TO THE CYTOCIDAL EFFECT OF TUMOR NECROSIS FACTOR
IN HETEROKARYONS FORMED BY FUSION OF RESISTANT AND SENSITIVE CELLS
  NOPHAR Y; HOLTMANN H; BER R; WALLACH D
  DEP. VIROL., WEIZMANN INST. SCI., REHOVOT 76100, ISRAEL.
  J IMMUNOL 140 (10). 1988. 3456-3460. CODEN: JOIMA
  Full Journal Title: Journal of Immunology
  Language: ENGLISH
 32/3/31
             (Item 14 from file: 5)
6102312
            BIOSIS Number: 34104619
  REGULATION OF CELL RESPONSE TO TUMOR NECROSIS FACTOR
  WALLACH D; NOPHAR Y; ADERKA D; ISRAEL S; HAHN T; ENGELMANN H; HOLTMANN H
  WEIZMANN INST. SCI., REHOVOT 76100, ISRAEL.
  INTERNATIONAL CONFERENCE ON TUMOR NECROSIS FACTOR AND RELATED CYTOTOXINS.
HEIDELBERG, WEST GERMANY, SEPTEMBER 14-18, 1987. IMMUNOBIOLOGY 175 (1-2).
1987.
     42.
            CODEN: IMMND
  Language: ENGLISH
  Document Type: CONFERENCE PAPER
 32/3/32
            (Item 15 from file: 5)
5977388
            BIOSIS Number: 84109953
  DOWN REGULATION OF THE RECEPTORS FOR TUMOR NECROSIS FACTOR BY INTERLEUKIN
1 AND 4-BETA PHORBOL-12-MYRISTATE-13-ACETATE
  HOLTMANN H; WALLACH D
  DEP. VIROL., WEIZMANN INST. SCI., REHOVOT 76100, ISR.
  J IMMUNOL 139 (4). 1987. 1161-1167. CODEN: JOIMA
  Full Journal Title: Journal of Immunology
  Language: ENGLISH
 32/3/33
             (Item 16 from file: 5)
5409320
            BIOSIS Number: 82054123
  BINDING OF HUMAN TUMOR NECROSIS FACTOR TO HIGH-AFFINITY CELL SURFACE
RECEPTORS EFFECT OF INTERFERON
 ISRAEL S; HAHN T; HOLTMAN H; WALLACH D
DEP. VIROL., WEIZMANN INS. SCI., REHOVOT, ISR.
  IMMUNOL LETT 12 (4). 1986. 217-224. CODEN: IMLED
```

```
**** 15 standard deviations above mean ****
                    HSV-1<u>→</u>B and surrounding regi
   7. N71302
                                                     3971
                                                                   759
                                                                        15.15
                     **** Standard deviations about
                                                        mean ****
   8. 010613
                    Rianodin receptor gene.
                                                    15672
                                                              22
                                                                   700
                                                                        13.95
   9. 006331
                   Human IL-2R beta chain.
                                                     4035
                                                              22
                                                                   695
                                                                        13.84
  10. 005872
                    Sequence encoding human inter
                                                     4035
                                                              22
                                                                   693
                                                                        13.80
  11. N70938
                   DNA fragment contq. streptomy
                                                     3830
                                                              23
                                                                   691
                                                                        13.76
  12. N82026
                    Cloned p2.1 insert encodes hu
                                                     3640
                                                              26
                                                                   690
                                                                        13.74
  13. 003665
                   Sequence homologous to Drosop
                                                     2465
                                                              22
                                                                   689
                                                                        13.72
  14. N70834
                   L-Tryptophan production.
                                                     7726
                                                              21
                                                                   687
                                                                        13.68
  15. Q11707
                    Immunoglobulin D-region heavy
                                                    14928
                                                              23
                                                                   687
                                                                        13.68
  16. Q13402
                   Human alpha-2 plasmin inhibit
                                                     2243
                                                              15
                                                                   687
                                                                        13.68
  17. Q11010
                   Fibulin C.
                                                     2200
                                                              19
                                                                   683
                                                                        13.60
  18. N92325
                   Human alpha-2-plasmin inhibit
                                                     2249
                                                                   683
                                                              15
                                                                        13.60
  19. N80944
                    Alpha-2 plasmin inhibitor pre
                                                     2189
                                                              15
                                                                   681
                                                                        13.56
  20. 005831
                    Cardiac sodium channel gene.
                                                              21
                                                                   681
                                                     7555
                                                                        13.56
1. US-07-625-668A-1 (1-2175)
   012215
                Type I TNF receptor.
ID
      Q12215 standard; DNA; 2176 BP.
AC
      012215;
DT
      12-SEP-1991
                   (first entry)
DE
      Type I TNF receptor.
KW
      Tumour Necrosis Factor; TNF; binding protein; TBP-I; ss.
OS
      Homo sapiens.
FH
                      Location/Qualifiers
      Keu
FT
                       244..246
      terminator
FT
      /*tag= a
FT
      /note= "in-frame termination codon"
FT
      CDS
                      256..1620
FT
      /*tag=
FT
      /product= type I TNF receptor
FT
                      256..318
      siq_peptide
FT
      /*tag= b
FT
      mat_peptide
                      319..1620
FT
      /*tag= c
FT
      misc RNA
                      319..864
FT
      /*tag= d
FT
      /label= soluble_domain
FT
      /note= "may be 2 codons shorter or a few codons
FT
      longer"
FT
      misc_feature
                      376..414
FT
      /*tag= e
      /note= "TBP-I derived sequence"
FT
      misc_feature
FT
                      583..627
FT
      /*tag= f
      /note= "TBP-I derived sequence"
FT
FT
      misc_feature
                      850..858
FT
      /*tag=
FT
      /note= "TBP-I derived sequence"
FT
      misc_RNA
                       889..957
FT
      /*tag= h
```

FT

/label= transmembrane_domain

385..504

505..633

634..756

757..858

repeat_unit

/*tag= i

/number= 1

/*tag= j

/*tag= k

/*tag= 1

/number= 3

repeat_unit

/number= 2

repeat_unit

repeat_unit

0

0

0

0

0

0

0

0

0

0

0

0

0

```
2070
                                        2060
   ACTAATAGAAACTTGGCACT<u>CC</u>TGTGCCCTCTGCCTGGACAAGCACAT<u>A</u>GCAAGCTGAACTGTCCTAAGGCA
   11111111111111
                       ACTAATAGAAACTTGGCACTCCTGTGCCCTCTGCCTGGACAAGCACATAGCAAGCTGAACTGTCCTAAGGCA
   2020
            2030
                     2040
                              2050
                                       2060
                                               2070
  2090
           2100
                    2110
                             2120
                                      2130
                                               2140
                                                        2150
   2090
          2100
                   2110
                            2120
                                     2130
                                              2140
                                                       2150
                                                                2160
 2160
         2170
                X
   TAAAAAAAAAAAAAA
   111111111111111111
   TAAAAAAAAAAAAAA
        2170
                X
2. US-07-625-668A-1 (1-2175)
  006285
              Human Tumour Necrosis Factor-Receptor cDNA insert.
 ID
     Q06285 standard; DNA; 2141 BP.
 AC
     Q06285;
 DT
     29-JAN-1991
                (first entry)
 DE
     Human Tumour Necrosis Factor-Receptor cDNA insert.
KW
     Tumour necrosis factor binding protein; TNF-BP; TNF-receptor;
 KW
     lambdaTNF-R2; raTNF-R8; ss.
 05
     Homo sapiens.
 FH
     Keu
                   Location/Qualifiers
 FT
     CDS
                   213..1577
 FT
     /*tag= a
FT
     /label=huTNF-R
 PN
     EP-393438-A.
PD
     24-DCT-1990.
 PF
     06-APR-1990; 106624.
     21-APR-1989; DE-913101.
 PR
     21-JUN-1989; DE-920282.
PR
PA
     (BOEH ) BOEHRINGER INGELHEIMINT.
PI
     Hauptmann R, Himmler A, Maurer-Fogy I, Stratowa C;
     WPI; 90-321987/43.
DR
     P-PSDB; R07451.
 DR
PT
     DNA encoding TNF binding protein and TNF- receptor - used in
 PT
     tumour treatment and to understand mechanismsm to TNF action
PS
     Disclosure; Fig 91(1-2); 51pp; German.
 CC
     raTNF-R8 (Q06284) was used to screen the HS913T cDNA library.
 CC
     LambdaTNF-R2 encodes the complete human TNF-R2 and was used to
 CC
     construct a plasmid (pADTNF-R) expressing the product the same way
 CC
     as pADTNF-BP (see Q06282).
 CC
     See also 006282-006285.
SQ
               2141 BP;
                         455 A;
                                  633 C;
                                           593 G;
     Sequence
                                                    460 T;
Initial Score
                  1711
                       Optimized Score
                                          2087
                                               Significance = 42.35
Residue Identity =
                   98%
                       Matches
                                          2097
                                               Mismatches
                                                                35
                                                           ==
Gaps
                     2
                       Conservative Substitutions
                                                                0
           Х
                 50
                          60
                                   70
                                            80
                                                     90
                                                             100
   ACTGGAGCCTCAGTCCAGAGAATTCTGAGAAAATTAAAGCAGAGAGGAGGGGGAGAGATCACTGGGACCAGGC
                                                  1 1 1
                         11 1
            GAATTCTCTGGACTGAGGCTCCAGTTCTGGCCTTTGGGGTTCA-AGATCACTGGGACCAGGC
                   10
                            20
                                     30
                                              40
                                                        50
                                                                60
                                 140
      110
               120
                        130
                                         150
                                                           170
                                                  160
   CGTGATCTCTATGCCCGAGTCTCAACCCTCAACTGTCACCCCAAGGCACTTGGGACGTCCTGGACAGACCGA
```


CGTGATCTCTATGCCCGAGTCTCAACCCTCAACTGTCACCCCAAGGCACTTGGGACGTCCTGGACAGACCGA


2040

2050

2080

2020





```
FT
     poluA_signal
                   2145..2150
FT
     /*tag= m
     EP-433900-A.
PN
     26-JUN-1991.
PD
PF
     13-DEC-1990; 124133.
     13-DEC-1989; IL-092697.
PR
     12-JUL-1990; IL-095064.
PR
PA
     (YEDA ) YEDA RES & DEV CO LTD.
PΙ
     Wallach D, Nophar Y, Kemper O, Engelmann H, Brakebusch C;
     Aderka D;
PΙ
     WPI; 91-186774/26.
DR
DR
     P-PSDB; R12550.
PT
     Recombinant tumour necrosis factor binding protein I - prepd. by
PT
     transfecting eukaryotic cells with vector contq. deoxyribonucleic
PT
     acid encoding human type T TNF receptor or soluble domain
PS
     Disclosure; Fig 1(D); 30pp; English.
CC
     The Tumour Necrosis Factor Binding Protein I is the soluble form of
CC
     type I TNF-receptor and constitutes a fragment of the cell surface
CC
     form of this receptor, corresp. to its extracellular domain.
CC
     There is no characteristic poly(A) addition signal near the 3' end
CC
     of the cDNA.
                 The sequence ACTAAA (tag m) may serve as an
CC
     alternative to this signal, but with low efficiency.
CC
     See also Q12212-15.
SQ
              2176 BP;
                         475 A;
                                  644 C;
                                           602 G;
                                                    455 T;
     Sequence
                  1800
Initial Score
                       Optimized Score
                                          2167
                                               Significance = 43.99
                   99%
Residue Identity
                       Matches
                                          2172
                                               Mismatches
Gaps
                     1
                       Conservative Substitutions
                                                                0
                                                      60
                   20
                            30
                                     40
                                              50
                                                               70
          10
   CGGCCCAGTGATCTTGAACCCCAAAGGCCAGAACTGGAGCCTCAGTCCAGAGAATTCTGAGAAAATTAAAGC
   CGGCCCAGTGATCTTGAACCCCAAAGGCCAGAACTGGAGCCTCAGTCCAGAGAATTCTGAGAAAATTAAAGC
                                     40
   Х
          10
                   20
                            30
                                             50
                                                      60
                 90
        80
                         100
                                           120
                                                    130
                                                             140
                                  110
   AGAGAGGAGGGGAGACACTGGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACCCTCAACTGTCACC
   AGAGAGGAGGGGAGATCACTGGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACCCTCAACTGTCACC
                 90
        80
                         100
                                  110
                                           120
                                                    130
                                                             140
      150
              160
                       170
                                180
                                         190
                                                  200
                                                           210
   CCAAGGCACTTGGGACGTCCTGGACAGACCGAGTCCCGGGGAAGCCCCAGCACTGCCGCTGCCACACTGCCCT
   CCAAGGCACTTGGGACGTCCTGGACAGACCGAGTCCCGGGGAACCCCCAGCACTGCCGCTGCCACACTGCCCT
              160
                       170
                                180
                                         190
                                                  500
    220
             230
                     240
                              250
                                       260
                                                270
                                                         280
   GAGCCCAAATGGGGGAGTGAGAGGCCATAGCTGTCTGGCATGGGCCTCTCCACCGTGCCTGACCTGCTGCTG
   GAGCCCAAATGGGGGAGTGAGAGGCCATAGCTGTCTGGCATGGCCTCTCCACCGTGCCTGACCTGCTGCTG
    220
             230
                     240
                              250
                                                         280
                                       260
                                                270
  290
           300
                                              340
                    310
                             320
                                      330
                                                       350
                                                                360
   CCGCTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGGTTATTGGACTGGTCCCTCACCTAGGG
   CCGCTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGGTTATTGGACTGGTCCCTCACCTAGGG
  290
                                                                360
           300
                    310
                             320
                                      330
                                              340
                                                       350
         370
                  380
                           390
                                    400
                                             410
                                                     420
                                                              430
   GACAGGGAGAGAGAGATAGTGTGTCCCCCAAGGAAAATATATCCACCCTCAAAATAATTCGATTTGCTGT
   TGTGTCCCCAAGGAAAATATATCCAq
                                               TCAAAATAATTCGATTTGCAGT
   GACAGGGAGAAGAGAGATAG
                  380
                           390
                                    400
         370
                                                     420
                                                              430
```

/number= 4

FT

Ont

Number of residues: 15631576 Number of sequences optimized: 4191

The scores below are sorted by optimized score. Significance is calculated based on optimized score.

A 100% identical sequence to the query sequence was not found.

The list of best scores is:

| | | | lnit. | Opt. | | |
|-----------------------------|------------------------|------------|------------|-------|-------|-------|
| Sequence Name | Description | Le | ngth Score | Score | Sig. | Frame |
| | **** 47 standard devi | ations abo | ve mean ** | ** | | |
| 1. HUMTNFRB | Homo sapiens tumor nec | rosis f | 2111 1713 | 2085 | 47.96 | 0 |
| 2. HUMTNFR | Human tumor necrosis f | actor r | 2087 2074 | 2077 | 47.75 | 0 |
| 3. HUMTNFRC | Human tumor necrosis f | `actor r : | 2112 1660 | 2074 | 47.67 | 0 |
| | **** 38 standard devi | ations abo | ve mean ** | * * | | |
| 4. HSTNFBP | Human tumor necrosis f | `actor r | 2050 1625 | 1718 | 38.49 | 0 |
| 5. HUMTNFRP | Human tumor necrosis f | actor r | 2050 1625 | 1718 | 38.49 | 0 |
| | **** 24 standard devi | ations abo | ve mean ** | * * | | |
| MUSTNFRE5 | Mouse mRNA for 55-kDa | tumor n | 2179 817 | 1193 | 24.94 | 0 |
| 7. MUSP55R | Murine mRNA for p55 tu | mor nec | 2063 795 | 1160 | 24.09 | 0 |
| 8. MUSMTNFR1 | Mouse tumor necrosis f | `actor r | 2048 775 | 1159 | 24.07 | 0 |
| | **** 23 standard devi | ations abo | ve mean ** | ** | | |
| 9. MUSTNFR2 | Murine tumor necrosis | factor | 1956 812 | 1136 | 23.47 | 0 |
| | **** 21 standard devi | ations abo | ve mean ** | ** | | |
| 10. RATTNFR | Rat tumor necrosis fac | tor rec | 2130 793 | 1042 | 21.05 | 0 |
| | **** 12 standard devi | ations abo | ve mean ** | * * | | |
| 11. CHKMYB15 | Chicken c-myb oncogene | DNA fo | 3200 28 | 706 | 12.38 | 0 |
| 12. PSESDSAB11 | Pseudomonas sp. (strai | n ATCC | 3510 25 | 704 | 12.33 | 0 |
| 13. XAADHLA | X.autotrophicus haloal | kane de 📑 | 3041 28 | 697 | 12.15 | 0 |
| 14. DROHBG | Drosophila melanogaste | er hunch | 7680 23 | 696 | 12.12 | 0 |
| 15. HUMINT2 | Human int-2 proto-onco | gene. 1 | 1608 25 | 696 | 12.12 | 0 |
| <pre>16. HUMTGFB</pre> | Human transforming gro | owth fac : | 2744 24 | 695 | 12.10 | 0 |
| 17. HS1GLYB | xerpes simplex virus t | ype 1 g ' | 7756 27 | 695 | 12.10 | 0 |
| 18. M21629 | Figure 2. Nucleotide s | equence ' | 7756 27 | 695 | 12.10 | 0 |
| 19. HUMLARR | Human mRNA for LCA-hor | nolog.L | 7702 25 | | 12.07 | 0 |
| 20. SUSAL1COL | Strongylocentrotus pur | puratus (| 4245 23 | 694 | 12.07 | 0 |
| | | | | | | |

1. US-07-625-668A-1 (1-2175)

CDS

HUMTNFRB Homo sapiens tumor necrosis factor receptor mRNA,

187..1554


/note="55 kDa"


| LOCUS DEFINITION ACCESSION | HUMTNFRB 2111 bp ss-mRNA PRI 14-NOV-1990 Homo sapiens tumor necrosis factor receptor mRNA, complete cds. M58286 M33480 |
|----------------------------------|--|
| KEYWORDS | tumor necrosis factor receptor. |
| SOURCE | Human cell line HL60, cDNA to mRNA. |
| ORGANISM | Homo sapiens |
| | Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia; |
| | Theria; Eutheria; Primates; Haplorhini; Catarrhini; Hominidae. |
| REFERENCE | 1 (bases 1 to 2111) |
| AUTHORS | Loetscher, H., Pan, YC.E., Lahm, HW., Gentz, R., Brockhaus, M., Tabuchi, H. and Lesslauer, W. |
| TITLE | Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor |
| JOURNAL | Cell 61, 351-359 (1990) |
| STANDARD | simple staff_review |
| FEATURES | Location/Qualifiers |

```
/gene="TNF receptor"
                   /codon_start=1
                   translation="MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVC/
                   PQGKYIHPQNNSICCTKCHKGTYLYNDCPGPGQDTDCRECESGSFTASENHLRHCLSC
                   SKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQE
                   KONTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVI
                   FFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPT
                   PGFTPTLGFSPVPSSTFTSSSTYTPGDCPNFAAPRREVAPPYQGADPILATALASDPI
                   PNPLQKWEDSAHKPQSLDTDDFATLYAVVENVPPLRWKEFVRRLGLSDHEIDRLELQN
                   GRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLGCLEDIEEALCGPAALPPA
                   PSLLR"
                   187..273
     sig_peptide
                   /product="tumor necrosis factor receptor"
                   /gene="TNF receptor"
                   /codon_start=1
     mat_peptide
                   274..1551
                   /product="tumor necrosis factor receptor"
                   /gene="TNF receptor"
                   /codon_start=1
BASE COUNT
               445 a
                      629 c
                              587 g
                                      450 t
ORIGIN
Initial Score
                  1713
                       Optimized Score
                                          2085
              =
                                               Significance = 47.96
                                          2090
Residue Identity
                   99%
                       Matches
                                               Mismatches
                                                           =
              =
                                                               16
Gaps
                     1
                       Conservative Substitutions
                                                                0
  60
           70
                    80
                             90
                                     100
                                             110
                                                      120
                                                               130
   AGAAAATTAAAGCAGAGAGGAGGGGAGATCACTGGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACC
                 1 11 11
                           GAATTCGGGGGGGTTCAAGATCACTGGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACC
            χ
                   10
                            20
                                     30
                                             40
                                                      50
                                                               60
                          160
        140
                 150
                                   170
                                            180
                                                     190
                                                             500
   CTCAACTGTCACCCCAAGGCACTTGGGACGTCCTGGACAGACCGAGTCCCGGGAAGCCCCAGCACTGCCGCT
   CTCAACTGTCACCCCAAGGCACTTGGGACGTCCTGGACAGACCGAGTCCCGGGAAGCCCCAGCACTGCCGCT
        70
                 80
                          90
                                  100
                                           110
                                                    120
                                                             130
       210
               220
                        230
                                 240
                                          250
                                                   260
                                                            270
   GCCACACTGCCCTGAGCCCAAATGGGGGAGTGAGAGGCCATAGCTGTCTGGCATGGGCCTCTCCACCGTGCC
   GCCACACTGCCCTGAGCCCAAATGGGGGGGTGAGAGGCCATAGCTGTCTGGCATGGGCCTCTCCACCGTGCC
      140
              150
                       160
                                170
                                                  190
                                         180
                                                           200
              290
     280
                      300
                               310
                                        320
                                                 330
                                                          340
   TGACCTGCTGCTGCCGCTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGGTTATTGGACTGGT
   TGACCTGCTGCCGCTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGGTTATTGGACTGGT
    210
                     230
             220
                              240
                                       250
                                                260
                                                         270
   350
                     370
                                      390
            360
                              380
                                               400
                                                        410
   CCCTCACCTAGGGGACAGGGAGAGAGAGATAGTGTGTGTCCCCAAGGAAAATATATCCACCCTCAAAATAA
   CCCTCACCTAGGGGACAGGGGAGAGAGATAGTGTGTGTCCCCAAGGAAAATATATCCACCCTCAAAATAA
           290
  280
                    300
                             310
                                     320
                                              330
                                                       340
                                                                350
                   440
 420
          430
                            450
                                     460
                                             470
                                                      480
                                                               490
   TTCGATTTGCTGTACCAAGTGCCACAAAGGAACCTACTTGTACAATGACTGTCCAGGCCCGGGGCAGGATAC
   TTCGATTTGCTGTACCAAGTGCCACAAAGGAACCTACTTGTACAATGACTGTCCAGGCCCGGGGCAGGATAC
         360
                  370
                           380
                                    390
                                             400
                                                      410
                                                              420
        500
                 510
                          520
                                   530
                                            5
                                                     550
                                                             560
```

GGACTGCAGGGAGTGTGAGAGCGGCTCCTTCACCGCTTCAGAAAACCACCTCAGACACTGCCTCAGCTGCTC

/product="tumor necrosis factor receptor"





```
2010
                        2030
              2020
                                  2040
                                            2050
                                                       2060
                                                                 2070
                        2170
    2150
              2160
    AAAATTCTGAAGTTAAAAAAAAAAAAAAAA
    AAAATTCTGAAGTTAAAAAAAAAAACCCGAATTC
  2080
            2090
                      2100
                                2110
2. US-07-625-668A-1 (1-2175)
                Human tumor necrosis factor receptor mRNA, complet
 LOCUS
             HUMTNER
                          2087 bp ss-mRNA
                                                     PRI
                                                                15-SEP-1990
             Human tumor necrosis factor receptor mRNA, complete cds.
 DEFINITION
 ACCESSION
             M33294
 KEYWORDS
             cell surface receptor; tumor necrosis factor receptor.
 SOURCE
             Human placenta, cDNA to mRNA.
   DRGANISM
             Homo sapiens
             Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
             Theria; Eutheria; Primates; Haplorhini; Catarrhini; Hominidae.
 REFERENCE
             1
                (sites)
   AUTHORS __ Schall, T.J., Lewis, M., Koller, K.J., Lee, A., Rice, G.C., Wong, G.H.,
             Getanaga,T., Granger,G.A., Lentz,R., Raab,H., Kohr,W.J. and
             Goeddel, D.V.
   TITLE
             Molecular cloning and expression of a receptor for human tumor
             necrosis factor
   JOURNAL
             Cell (1990) In press
   STANDARD
             full staff_review
 REFERENCE
                (bases 1 to 2087)
   AUTHORS
             Schall, T.J., Lewis, M., Koller, K.J., Lee, A., Rice, G.C., Wong, G.H.,
             Gatanaga, T., Granger, G.A., Lentz, R., Raab, H., Kohr, W.J. and
             Goeddel, D.V.
   TITLE
             Molecular cloning and expression of a receptor for human tumor
             necrosis factor
   JOURNAL
             Cell 61, 361-370 (1990)
             full staff review
   STANDARD
 COMMENT
             Draft entry and compuber-readable sequence for [1] kindly submitted
             by T.Schall, 26-MARP1990.
 FEATURES
                      Location/Qualifiers
      CDS
                      182..1549
                      /note="tumor necrosis factor receptor"
                      /codon start=1
                      translation="MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVC/
                      POGKYIHPONNSICCTKCHKGTYLYNDCPGPGODTDCRECESGSFTASENHLRHCLSC
                      SKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQE
                      KQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVI
                      FFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPT
                      PGFTPTLGFSPVPSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPI
                      PNPLQKWEDSAHKPQSLDTDDPATLYAVVENVPPLRWKEFVRRLGLSDHEIDRLELQN
                      GRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLGCLEDIEEALCGPAALPPA
                      PSLLR"
 BASE COUNT
                 433 a
                          624 c
                                   581 g
                                            449 t
 DRIGIN
Initial Score
                     2074
                           Optimized Score
                                                2077
                                                      Significance = 47.75
Residue Identity =
                      99%
                           Matches
                                                2077
                                                      Mismatches
                                                                         10
Gaps
                        0
                           Conservative Substitutions
                                                                          0
                  80
                                     100
                                               110
                                                         120
                                                                    130
    ATTAAAGCAGAGAGGAGGGGAGATCACTGGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACCCTCAA
                          CTTTGGGGTTCAAGATCACTGGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACCCTCAA
                      10
                                20
                                          30
                                                    40
                                                              50
                                                                         60
```

140

150


160


170

180

190


200







AGGGACGCTATGCCTCATGCCCGTTTTGGGTGTCCTCACCAGCAAGGCTGCTCGGGGGCCCCTGGTTCGTCC AGGGACGCTATGCCTCATGCCCGTTTTGGGTGTCCTCACCAGCAAGGCTGCTCGGGGGCCCCTGGTTCGTCC ATGTTACACTAATAGAAACTTGGCACTCCTGTGCCCTCTGCCTGGACAAGCACATAGCAAGCTGAACTGTCC ATGTTACACTAATAGAAACTTGGCACTCCTGTGCCCTCTGCCTGGACAAGCACATAGCAAGCTGAACTGTCC CTGAAGTTAAAAAAAAAAA CTGAAGTTA Х 3. US-07-625-668A-1 (1-2175) **HUMTNFRC** Human tumor necrosis factor receptor (TNF receptor LOCUS HUMTNFRC 2112 bp ss-mRNA PRI 30-SEP-1991 DEFINITION Human tumor necrosis factor receptor (TNF receptor) mRNA, complete cds. ACCESSION M63121 M75861 **KEYWORDS** tumor necrosis factor receptor. SOURCE Human cDNA to mRNA. **ORGANISM** Homo sapiens Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia; Theria; Eutheria; Primates; Haplorhini; Catarrhini; Hominidae. REFERENCE (bases 1 to 2112) **AUTHORS** Himmler, A., Maurer-Fogy, I., Kroenke, M., Scheurich, P., Pfizenmaier, K., Lantz, M., Olsson, I., Hauptmann, R., Stratowa, C. and TITLE Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein DNA Cell Biol. 9, 705-715 (1990) **JOURNAL** STANDARD simple staff_entry **FEATURES** ⊾ion/Qualifiers Lo 207.293 sig_peptide /gene="TNF receptor"

```
/codon_start=1
    CDS
                 207.1574
                    luct="tumor necrosis fact
                                         receptor"
                 /gene="TNF receptor"
                 /codon_start=1
                 /translation="MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVC
                 PQGKYIHPQNNSICCTKCHKGTYLYNDCPGPGQDTDCRECESGSFTASENHLRHCLSC
                 SKCRKEMG@VEISSCTVDRDTVCGCRKN@YRHYWSENLF@CFNCSLCLNGTVHLSC@E
                 K@NTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLP@IENVKGTEDSGTTVLLPLVI
                 FFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPT
                 PGFTPTLGFSPVPSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPI
                 PNPLQKWEDSAHKPQSLDTDDPATLYAVVENVPPLRWKEFVRRLGLSDHEIDRLELQN
                 GRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLGCLEDIEEALCGPAALPPA
                 PSLLR"
                 294..1571
    mat_peptide
                 /product="tumor necrosis factor receptor"
                 /gene="TNF receptor"
                 /codon_start=1
BASE COUNT
                    632 c
                           589 g
             435 a
                                  456 t
DRIGIN
Initial Score
                                     2074
             =
                1660
                    Optimized Score
                                          Significance = 47.67
Residue Identity
            =
                 98%
                    Matches
                                     2084
                                                        27
                                          Mismatches
                  2
Gaps
                     Conservative Substitutions
                                                         0
                          70
   40
          50
                                  08
                                          90
                  60
                                                 100
                                                         110
   TCTGGACTGAGGCTCCAGTTCTGGCCTTTGGGGTTCA-AGATCACTGGGACCAGGCCGTGAT
          Χ
                 10
                        20
                                30
                                         40
                                                 50
                                                         60
        120
                130
                        140
                                150
                                       160
                                               170
                                                       180
   CTCTATGCCCGAGTCTCAACCCTCAACTGTCACCCCAAGGCACTTGGGACGTCCTGGACAGACCGAGTCCCG
   CTCTATGCCCGAGTCTCAACCCTCAACTGTCACCCCAAGGCACTTGGGACGTCCTGGACAGACCGAGTCCCG
        70
                        90
                               100
                                       110
                                              120
                                                      130
      190
              200
                      210
                              220
                                      230
                                              240
                                                     250
   GGAAGCCCCAGCACTGCCGCTGCCACTGCCCTGAGCCCAAATGGGGGAGTGAGAGGCCATAGCTGTCTGG
   GGAAGCCCCAGCACTGCCGCTGCCACACTGCCCTGAGCCCAAATGGGGGAGTGAGAGGCCATAGCTGTCTGG
      140
             150
                     160
                             170
                                     180
                                             190
                                                     200
     260
             270
                     280
                            290
                                    300
                                            310
                                                    320
   CATGGGCCTCTCCACCGTGCCTGACCTGCTGCTGCCGCTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCC
   CATGGGCCTCTCCACCGTGCCTGACCTGCTGCTGCCACTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCC
    210
            220
                    230
                            240
                                   250
                                           260
                                                   270
   330
           340
                   350
                           360
                                   370
                                          380
                                                  390
   280
          290
                  300
                          310
                                  320
                                          330
                                                  340
  400
          410
                 420
                         430
                                 440
                                         450
                                                 460
                                                         470
   ATATATCCACCCTCAAAATAATTCGATTTGCTGTACCAAGTGCCACAAAGGAACCTACTTGTACAATGACTG
   ATATATCCACCCTCAAAATAATTCGATTTGCTGTACCAAGTGCCACAAAGGAACCTACTTGTACAATGACTG
 350
         360
                 370
                        380
                                390
                                        400
                                                410
                                                        420
        480
                490
                        500
                                510
                                       520
                                               530
                                                       540
   TCCAGGCCCGGGGCAGGATACGGACTGCAGGGAGTGTGAGAGCGGCTCCTTCACCGCTTCAGAAAACCACCT
   TCCAGGCCCGGGGCAGGATACGGACTGCAGGGAGTGTGAGAGCGGCTCCTTCACCGCTTCAGAAAACCACCT
```



```
4. US-07-625-668A-1 (1-2175)
  010883
               30kD TNF inhibitor precursor gene in lambda-gt10-7
 ID
     Q10883 standard; cDNA; 2088 BP.
AC
     010883;
DT
     13-MAY-1991
                 (first entry)
DE
     30kD TNF inhibitor precursor gene in lambda-gt10-7ctnfbp.
KW
     Tumour necrosis factor; inhibitor; ss.
os
     Homo sapiens.
FH
     Keu
                    Location/Qualifiers
FT
     CDS
                    171..1536
 FT
     /*tag=
PN
     AU9058976-A.
PD
     24-JAN-1991.
PF
     16-JUL-1990; 058976.
PR
     18-JUL-1989; US-381080.
     11-DEC-1989; US-450329.
PR
     07-FEB-1990; US-479661.
PR
     (SYNE-) SYNERGEN INC.
PA
DR
     WPI; 91-073847/11.
     P-PSDB; R10986.
DR
PT
     Tumour necrosis factor inhibitor - for suppression of TNF-alpha
     and -beta, useful as therapeutic agent.
PT
PS
     Disclosure; Fig 21; 142pp; English.
CC
     The sequence encodes the entire 30 kD TNF inhibitor. The clone from
CC
     which the sequence was obtd. was isolated from a cDNA library
CC
     prepd. from RNA form U937 cells treated with PMA/PHA.
                                                          The whole
CC
     gene can be inserted into expression vectors for prepn. of TNF
CC
     inhibitor for use in the treatment of inflammatory and degenerative
CC
CC
     See also Q10878, Q10884 and Q10907.
SQ
     Sequence
               2088 BP;
                           439 A;
                                    626 C;
                                             578 G;
                                                       445 T;
Initial Score
                   1713
                         Optimized Score
                                            2077
                                                  Significance = 42.14
                    99%
Residue Identity
               =
                         Matches
                                            2082
                                                  Mismatches
                                                              =
Gaps
                      1
                         Conservative Substitutions
                                                              =
                                                                    0
    80
              90
                      100
                               110
                                         120
                                                  130
                                                            140
   GGAGGGGAGAGATCACTGGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACCCTCAACTGTCACCCCAAG
             GATCACTGGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACCCTCAACTGTCACCCCAAG
             χ
                    10
                             20
                                       30
                                                40
                                                          50
                                                                   60
 150
                              180
           160
                    170
                                       190
                                                200
                                                          210
                                                                   220
   GCACTTGGGACGTCCTGGACAGACCGAGTCCCGGGAAGCCCCAGCACTGCCGCTGCCACACTGCCCTGAGCC
   GCACTTGGGACGTCCTGGACAGACCGAGTCCCGGGAAGCCCCAGCACTGCCGCTGCCACACTGCCCTGAGCC
         70
                            90
                  80
                                    100
                                                       120
                                             110
                                                                130
                            250
         230
                  240
                                     260
                                              270
                                                        280
                                                                 290
   CAAATGGGGGAGTGAGAGGCCATAGCTGTCTGGCATGGGCCTCTCCACCGTGCCTGACCTGCTGCTGCCGCT
   CAAATGGGGGAGTGAGAGGCCATAGCTGTCTGGCATGGGCCTCTCCACCGTGCCTGACCTGCTGCTGCCGCT
      140
                         160
               150
                                  170
                                            180
                                                     190
                                                              200
                          320
                                            340
       300
                310
                                   330
                                                      350
                                                               360
   GGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGGTTATTGGACTGGTCCCTCACCTAGGGGACAG
   GGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGGTTATTGGACTGGTCCCTCACCTAGGGGACAG
    210
             220
                       230
                                240
                                          250
                                                   260
                                                            270
     370
              380
                         70
                                 400
                                           410
                                                    420
                                                             430
   GGAGAAGAGAGATAGTGTGTGTCCCCAAGGAAAATATATCCACCCTCAAAATAATTCGATTTGCTGTACCAA
```





```
1870
               1880
                        1890
                                 1900
                                          1910
                                                   1920
        2030
                 2040
                          2050
                                            2070
                                   2060
                                                    2080
                                                             2090
   TAGAAACTTGGCACTCCTGTGCCCTCGGACAAGCACATAGCAAGCTGAACTGTCCTAAGGCAGGGGC
   TAGAAACTTGGCACTCCTGTCCCCTCTGCCTGGACAAGCACATAGCAAGCTGAACTGTCCTAAGGCAGGGGC
     1940
              1950
                               1970
                                                 1990
                      1960
                                        1980
                                                          2000
       2100
               2110
                        2120
                                 2130
                                          2140
                                                   2150
                                                            2160
   2010
            2020
                     2030
                             2040
                                      2050
                                               2060
                                                        2070
     2170
           Х
   AAAAAAAAAA
      111111
   CTCAAAAAAA
 2080
5. US-07-625-668A-1 (1-2175)
  006282
              Plasmid Tumour Necrosis Factor-Binding Protein 15
 ID
     Q06282 standard; DNA; 1334 BP.
 AC
     006282;
 DT
     29-JAN-1991
               (first entry)
 DE
     Plasmid Tumour Necrosis Factor-Binding Protein 15 cDNA insert.
     Tumour necrosis factor binding protein; TNF-BP; TNF-receptor;
KW
 KW
     pTNF-BP15; ss.
 08
     Homo sapiens.
 FH
     Keu
                   Location/Qualifiers
 FT
     CDS
                   213..1325
 FT
     /*tag= a
 FT
     /product=TNF-BP
 PN
     EP-393438-A.
     24-OCT-1990.
 PD
 PF
     06-APR-1990; 106624.
 PR
     21-APR-1989; DE-913101.
     21-JUN-1989; DE-920282.
 PR
 PA
     (BOEH ) BOEHRINGER INGELHEIMINT.
 PΙ
     Hauptmann R, Himmler A, Maurer-Fogy I, Stratowa C;
 DR
     WPI; 90-321987/43.
 DR
     P-PSDB; R07449.
 PT
     DNA encoding TNF binding protein and TNF- receptor - used in
 PT
     tumour treatment and to understand mechanismsm to TNF action
 PS
     Disclosure; Fig 1(1-3); 51pp; German.
     pTNF-BP15 is one of 30 positives clones in a screened cDNA library
 CC
 CC
     from induced TNF-induced fibrosarcoma cells. A TNF-BP had been
 CC
     isolated from the urine of patients with uraemia and probes/primers
 CC
     were constructed from the determined amino acid sequence.
 CC
     To produce a vector expressing a soluble form of TNF-binding
CC
     protein, this plasmid was cut with XmmI, amplified by PCR and the
 CC
     amplified DNA cut with BamHI and EcoRI.
 CC
     The resulting 0.75 kb DNA fragment was inserted into pT7/T3 alpha-19
CC
     (BRL) cut with the same enzymes to recover pTNF-BP. This was cut
CC
     with BamHI and EcoRI, and the recovered fragment inserted into
CC
     pAD-CMV1 (Q06283) to give the required plasmid pADTNF-BP.
CC
     See also 006282-006285.
SQ
              1334 BP;
     Sequence
                         299 A;
                                  409 C;
                                           342 G;
                                                    284 T;
nitial Score
                  1289
                       Optimized Score =
                                          1298
                                               Significance = 26.19
                                          1303
 esidue Identitu =
                   97%
                       Matches
                                               Mismatches
                                                               31
 aps
                     1
                       Conservative Substitutions
                                                                0
```

| F | 100- | * | * * | | | | | | | | |
|-------------|-------|-----|-----|-----|--------|----------|-----------|--------|---------|-----|---|
| | - * | | * | * | | | | | | | |
| S | _ | | * | * * | | | 4 | | | | |
| SEQUE | 50- | | | | | | • | | | | |
| 0 | | | | | * | | | | | | |
| Ū | | | | | | | | | | | |
| F | _ | | | 4 | ŧ | | | | | | |
| N | | | | | | | | | | | |
| Ċ | _ | | | | | | | | | | |
| - | _ | | | | | | | | | | |
| C E S | 10- | | | | * | | | | | | |
| - | - | | | | ^ | | | | | | |
| | _ | | | | | | | | | | * |
| | 5- | | | | | | | | | | * |
| | J - | | | | | | | | | | |
| | _ | | | | * | | | | | | |
| | _ | | | | ж | | | | | | |
| | _ | | | | | | | | | | |
| | _ | | | | | | | | | | |
| | | | | | | * | | | * | | |
| | 0 | | | | | * | | | * | | |
| | U | | | | | | | | 1 | | |
| СТ | DEV 0 | 1 | 2 | 3 | 1 4 | 5 | 1 | 1 7 | 1 | 1 | |
| 3 I | ORE 5 | 1 5 | | 37 | | 59 | -6 -70 | - | 8 92 | 9 | |
| 36 | OVE 7 | 15 | 26 | 3/ | 48 | 37 | 70 | 81 | 76 | 102 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

PARAMETERS

| Similarity matrix | Unitary | K-tuple | 2 | |
|-------------------------|---------|--------------------|----|--|
| Mismatch penalty | 5 | Joining penalty | 20 | |
| Gap penalty | 5.00 | Window size | 13 | |
| Gap size penalty | 0.26 | | | |
| Cutoff score | 0 | | | |
| Randomization group | 0 | | | |
| Initial scores to save | 20 | Alignments to save | 10 | |
| Optimized scores to sav | e 20 | Display context | 10 | |

SEARCH STATISTICS

| Scores: | Mean | Median | Standard Deviation |
|---------|--------------------|--------|--------------------|
| | 5 | 20 | 10.89 |
| Times: | CPU 00:02:00.00 | | Total Elapsed |

Number of residues: 1428997 Number of sequences optimized: 3856

The scores below are sorted by optimized score. Significance is calculated based on optimized score.

A 100% identical sequence to the query sequence was found:

| Sequence Name | Description | Length | Init. Score | • | Sig. | Frame |
|---------------|-------------------------------|--------|----------------|-----|-------|-------|
| 1. R10986 | 30kD TNF inhibitor precursor. | 455 | 455 | 455 | 41.34 | γ O 3 |

The list of other best scores is:

| Sequence N | ame De | scription | Length | Score | Score | Sig. | Frame |
|------------|--------|-----------|--------|-------|-------|------|-------|
| | | | | init. | Upt. | | |

```
Human 55kD TNF-binding protei
 2. R11082
                                                                   454
                                                      455
                                                            454
                                                                        41.25
                                                                                 0
 3. R12550
                  Tupe I TNF receptor.
                                                      455
                                                                   453
                                                                        41.15
                                                                                 0
                   **** 40 standard deviations above mean ****
 4. R07451
                  Human Tumour Necrosis Factor-
                                                     455
                                                            451
                                                                   451
                                                                        40.97
                                                                                 0
                   **** 33 standard deviations above mean ****
 5. R07449
                  Tumour Necrosis Factor-Bindin
                                                     371
                                                            371
                                                                   371
                                                                        33.62
                                                                                 0
                   **** 19 standard deviations above mean ****
 6. R07450
                  Rat Tumour Necrosis Factor-Re
                                                      461
                                                            240
                                                                   212
                                                                        19.02
                                                                                 0
                   **** 8 standard deviations above mean ****
 7. R10984
                  Partial sequence 30kD TNF inh
                                                      102
                                                                    96
                                                                         8.36
                                                                                0
                   **** 4 standard deviations above mean ****
 8. R11142
                  TNF-R deduced from mTNF-R clo
                                                      474
                                                                    55
                                                                         4.59
                                                                                 0
                         3 standard deviations above mean ****
 9. P70416
                  Polypeptide with IgE binding
                                                                    47
                                                     557
                                                              5
                                                                                0
                                                                         3.86
10. R13949
                  SUP-B27 t(1;19) translocation
                                                     736
                                                              9
                                                                    47
                                                                         3.86
                                                                                 0
11. R12914
                  Human Thyroid Stimulating Hor
                                                                    47
                                                                                0
                                                     764
                                                              6
                                                                         3.86
12. R13269
                  Human Thyroid Stimulating Hor
                                                     764
                                                              6
                                                                    47
                                                                         3.86
                                                                                0
13. R12505
                  Human thyroid stimulating hor
                                                                    47
                                                     764
                                                                         3.86
                                                                                 0
                                                              6
14. R13951
                  E2A/prl fusion protein TYPE I
                                                     825
                                                              9
                                                                    47
                                                                         3.86
                                                                                 0
15. R15158
                                                              9
                                                     742
                                                                    47
                  E2A/pr1 fusion protein TYPE I
                                                                         3.86
                                                                                 0
16. R13948
                  SUP-B27 t(1;19) translocation
                                                     819
                                                              9
                                                                    47
                                                                         3.86
                                                                                 0
17. R10656
                  Hepatic parenchymal cell grow
                                                     727
                                                              8
                                                                    46
                                                                         3.77
                                                                                0
18. P61048
                                                              5
                                                                    46
                                                                                0
                  A.nidulans phosphenol pyruvic
                                                    1085
                                                                         3.77
                                                                                0
19. R11254
                  Human IL-4 receptor.
                                                     825
                                                              5
                                                                    46
                                                                         3.77
20. R08406
                  Sequence deduced from env gen
                                                     846
                                                              6
                                                                    45
                                                                                0
                                                                         3.67
```

1. US-07-625-668A-2 (1-455) R10986 30kD TNF inhibitor precursor.

R10986 standard; Protein; 455 AA.

ID

SQ

Gaps

Initial Score

Residue Identity =

```
AC.
     R10986;
DT
     13-MAY-1991
                  (first entry)
DE
     30kD TNF inhibitor precursor.
KW
     Tumour necrosis factor; inhibitor.
     Homo sapiens.
05
FH
                     Location/Qualifiers
FT
                     40..41
     Cleavage-site
FT
     note=" cleavage gives active protein "
PN
     AU9058976-A.
PD
     24-JAN-1991.
PF
     16-JUL-1990; 058976.
PR
     18-JUL-1989; US-381080.
PR
     11-DEC-1989; US-450329.
PR
     07-FEB-1990; US-479661.
PA
     (SYNE-) SYNERGEN INC.
DR
     WPI; 91-073847/11.
DR
     N-PSDB; Q10883.
PT
     Tumour necrosis factor inhibitor - for suppression of TNF-alpha
PT
     and -beta, useful as therapeutic agent.
PS
     Disclosure; Fig 21; 142pp; English.
CC
     The sequence comprises the entire 30 kD TNF inhibitor. The clone
     from which the sequence was deduced was isolated from a cDNA
CC
CC
     library prepd. from RNA form U937 cells treated with PMA/PHA.
CC
     The whole gene can be inserted into expression vectors for prepn.
CC
     of TNF inhibitor for use in the treatment of inflammatory and
CC
     degenerative diseases. The active protein is claimed (Claim 8).
CC
     See also R10984 and R11001.
50
     Sequence
                455 AA;
5Q
     20 A; 27 R; 17 N; 21 D; 0 B; 30 C; 15 Q; 30 E; 0
                                                          Z; 30 G; 10 H;
```

13 I; 58 L; 20 K; 5 M; 14 F; 37 P; 36 S; 31 T; 5

Matches

Optimized Score

455

100

W; 13 Y; 23 V;

Significance = 41.34

=

0

0

Mismatches

455

451

=

Conservative Substitutions

```
PD
     20-MAR-1991.
PF
     31-AUG-1990; 116707.
PR
     12-SEP-1989; CH-003319.
     08-MAR-1990; CH-000746.
PR
PR
     20-APR-1990; CH-001347.
PA
     (HOFF ) HOFFMANN-LA ROCHE AG.
     Brockhaus M, Dembic Z, Gentz R, Lesslauer W, Lotscher H;
PΙ
PI
     Schlaeger EJ;
     WPI; 91-081851/12.
DR
DR
     N-PSDB; Q10955.
PT
     Insoluble tumour necrosis factor binding proteins - and DNA
PT
     encoding them, useful in pharmaceutical prods. and for antibody
PT
PS
     Claim 1; Fig 1; 26pp; German.
CC
     Partial amino acid sequences were determined for the 55 and 75kD
CC
     TNF-BPs (see R11072-R11081) and oligonucleotide primers were
CC
     synthesised based on these partial sequences. The primers were used
CC
     to produce a cDNA fragment for use as aprobe to screen a human
CC
     placental cDNA bank constructed in lambda gt11. Positive clones were
CC
     identifed and sequenced. DNA constructs comprising the TNF-BP coding
.cc
     sequence may also contain a fragment encoding a human Ig domain.
CC
     Recombinant constructs are used to transform cells to confer
CC
     improved TNF-binding properties.
CC
     See also 010956.
SQ
               455 AA;
     Sequence
SQ
     20 A; 27 R; 17 N; 21 D; 0
                             B; 30 C; 15 Q; 30 E; 0
                                                   Z; 30 G; 10 H;
SQ
     13 I; 57 L; 20 K; 5
                       M; 14 F; 37 P; 36 S; 31 T; 5
                                                   W; 13 Y; 24 V;
Initial Score
                    454
                        Optimized Score
                                            454
                                                 Significance = 41.25
Residue Identitu
                    99%
                                                 Mismatches
                        Matches
                                            454
                                                             =
                                                                  1
                     0
Gaps
                        Conservative Substitutions
                                                             =
                                                                  0
          10
                    20
                             30
                                      40
                                               50
                                                        60
                                                                 70
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   X
          10
                    20
                             30
                                      40
                                               50
                                                        60
                                                                 70
         80
                  90
                          100
                                   110
                                            120
                                                     130
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
         80
                  90
                          100
                                   110
                                            120
                                                      130
                                                               140
      150
               160
                        170
                                 180
                                          190
                                                    200
                                                             210
   NCSLCLNGTVHLSC@EK@NTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLP@IENVKGTEDSGTTVLLPL
   NCSLCLNGTVHLSC@EK@NTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLP@IENVKGTEDSGTTVLLPL
                                                   200
      150
               160
                        170
                                 180
                                          190
                                                             210
    220
             230
                      240
                               250
                                        260
                                                  270
                                                           280
   VIFFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
   VIFFGVCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
    220
             230
                      240
                               250
                                        260
                                                  270
                                                           280
  290
           300
                                       330
                    310
                              320
                                                340
                                                         350
                                                                  360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
  290
           300
                    310
                              320
                                       330
                                                340
                                                         350
                                                                  360
         370
                            390
                  380
                                     400
                                              410
                                                       420
                                                                430
   AVVENVPPLRWKEFVRRLGL
                       HEIDRLEL@NGRCLREA@YSMLATW|
```

AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG

ITPRREATLELLGRVLRDMDLLG

```
20
   X
          10
                           30
                                    40
                                             50
                                                     60
                                                              70
   	exttt{MGLSTVPDLLLPLVLLELLVGI} 	exttt{YPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC}
   MGLSTVPDLLLPLVLLELLVGTYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
                   20
          10
                                    40
                                             50
                           30
        80
                 90
                         100
                                 110
                                          120
                                                   130
                                                            140
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
                 90
        80
                         100
                                 110
                                          120
                                                   130
                                                           140
      150
              160
                       170
                                180
                                        190
                                                 200
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
              160
                       170
                                180
                                        190
                                                 200
                                                          210
    220
             230
                     240
                              250
                                       260
                                               270
                                                        280
   VIFFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
   VIFFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
    220
             230
                     240
                              250
                                       260
                                               270
                                                        280
  290
           300
                    310
                            320
                                             340
                                                      350
                                     330
                                                               360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDTDDPATLY
  290
           300
                    310
                            320
                                     330
                                             340
                                                      350
                                                               360
         370
                  380
                          390
                                   400
                                            410
                                                    420
                                                             430
   <u>AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG</u>
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
         370
                  380
                          390
                                   400
                                            410
                                                    420
                                                             430
       440
                450
   CLEDIEEALCGPAALPPAPSLLR
   CLEDIEEALCGPAALPPAPSLLR
       440
                450
                      X
2. US-07-625-668A-2 (1-455)
  R11082
             Human 55kD TNF-binding protein.
ID
     R11082 standard; Protein; 455 AA.
AC
     R11082;
DT
     24-MAY-1991
                (first entry)
DE
     Human 55kD TNF-binding protein.
KW
     Tumour Necrosis Factor; binding proteins; septic shock;
KW
     autoimmune glomerulonephritis; lymphokine; cytokine.
FH
                   Location/Qualifiers
FT
                   54
     Modified -site
FT
     /label= putative N-glycosylation site
FT
     Modified -site
                  145
FT
     /label= putative N-glycosylation site
FT
     Modified -site
                   151
FT
     /label= putative N-glycosylation site
FT
     Modified -site
                   270
FT
     /label= putative N-glycosylation site
                   212..230
FT
     Region
FT
     /label= transmembrane region
FT
     Peptide
                   1..28
FT
     /label= signal peptide
PN
     EP-417563-A.
```

```
370 380 390 400 410 420 430
440 450 A
```

```
CLEDIEEALCGPAALPPAPSLLR
    CLEDIEEALCGPAALPPAPSLLR
         440
                   450
3. US-07-625-668A-2 (1-455)
   R12550
                Type I TNF receptor.
 ΙD
      R12550 standard; Protein; 455 AA.
AC
DT
      12-SEP-1991 (first entry)
DE
      Type I TNF receptor.
KW
      Tumour Necrosis Factor; TNF; binding protein; TBP-I.
08
      Homo sapiens.
FH
      Keu
                      Location/Qualifiers
FT
      Peptide
                      1..21
FT
      /label= sig_peptide
FT
      Protein
                      22..455
FT
      /label= mat_protein
FT
      Domain
                      212..234
FT
      /label= transmembrane_domain
FT
      Region
                      41..53
FT
      /label= TBP-I derived sequence
FT
      Region
                      110..124
FT
      /label= TBP-I derived sequence
FT
                      199..201
      Region
FT
      /label= TBP-I derived sequence
FT
      Modified -site 54..56
FT
      /label= N-glycosylation_site
FT
      Modified -site 145..147
FT
      /label= N-glycosylation site
FT
      Modified -site 151..153
FT
      /label= N-glycosylation_site
FT
      Region
                      44..83
FT
      /label= repeat_1
FT
      Region
                      84..126
FT
      /label= repeat 2
FT
                      127..167
     Region
FT
      /label= repeat_3
FT
      Region
                      168..201
FT
      /label= repeat_4
FT
      Domain
                      21..203
      /label= soluble_domain
FT
FT
      /note= "may be 2 amino acids shorter or contain a
                              12-13-90
FT
      few additional amino acids"
PN
     EP-433900-A.
PD
     26-JUN-1991.
      13-DEC-1990; 124133.
PF
PR
      13-DEC-1989; IL-092697.
PR
      12-JUL-1990; IL-095064.
PA
      (YEDA ) YEDA RES & DEV CO LTD.
PΙ
      Wallach D, Nophar Y, Kemper O, Engelmann H, Brakebusch C;
PΙ
      Aderka D;
      WPI; 91-186774/26.
DR
DR
      N-PSDB; Q12215.
PT
      Recombinant tumour necrosis factor binding protein I - prepd. by
PT
      transfecting eukaryotic cells with vector contg. deoxyribonucleic
      acid encoding human type T TNF receptor or soluble domain
PT
```

The Tumour Necrosis Factor Binding Protein I is the soluble form of

type I TNF-receptor and constitutes a fragment of the cell surface

form of this receptor, corresp. to its extracellular domain.

PS

CC

CC

CC

Disclosure; Fig 1(D); 30pp; English.

```
The soluble proteins produced by the transfected cells secreted
 CC
     into the medium may have at the N-terminus the sequence Asp-Ser-Val
 CC
     (41-43), or the sequence Leu-Val-Pro (30-32) or Ile-Tyr-Pro (22-24)
 CC
     or any other sequence between Ile (21) and Asp (41).
CC
     See also 012212-15.
SQ
     Sequence
              455 AA;
SQ
     20 A; 27 R; 17 N; 21 D; 0
                            B; 30 C; 15 Q; 30 E; 0
                                                 Z; 30 G; 10 H;
SQ
     13 I; 58 L; 20 K; 5
                       M; 14 F; 37 P; 37 S; 31 T; 4
                                                 W; 13 Y; 23 V;
Initial Score
                   453
                       Optimized Score
                                          453
                                              Significance = 41.15
                   99%
Residue Identity
                                          453
              =
                       Matches
                                               Mismatches
                                                          =
                                                               2
                       Conservative Substitutions
Gaps
                    0
                                                               0
                   20
                           30
                                    40
                                             50
                                                              70
          10
                                                     60
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICSTKCHKGTYLYNDC
   χ
          10
                   20
                           30
                                    40
                                             50
                                                              70
                                                      60
        80
                 90
                         100
                                  110
                                          120
                                                   130
                                                            140
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
        80
                 90
                         100
                                  110
                                          120
                                                   130
      150
                       170
              160
                                180
                                        190
                                                 200
                                                          210
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
   NCSLCLNGTVHLSC@EK@NTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLP@IENVKGTEDSGTTVLLPL
      150
              160
                       170
                                180
                                        190
                                                 200
                                                          210
    220
            230
                     240
                              250
                                       260
                                               270
                                                        280
   VIFFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
   VIFFGLCLLSLLFIGLMYRY@RCKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
    220
             230
                     240
                              250
                                       260
                                               270
                                                        280
  290
           300
                   310
                            320
                                     330
                                              340
                                                      350
                                                               360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
  290
           300
                   310
                            320
                                     330
                                              340
                                                      350
         370
                  380
                          390
                                   400
                                            410
                                                     420
                                                             430
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAGYSMLATWRRRTPRREATLELLGRVLRDMDLLG
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
         370
                  380
                          390
                                   400
                                            410
                                                     420
                                                             430
       440
                450
                      X
   CLEDIEEALCGPAALPPAPSLLR
   CLEDIEEALCGPAALPPAPSLLR
       440
                450
                      X
  US-07-625-668A-2 (1-455)
  R07451
             Human Tumour Necrosis Factor-Receptor from lambdaT
ID
     R07451 standard; protein; 455 AA.
AC
     R07451;
DT
     29-JAN-1991
                (first entry)
DE
     Human Tumour Necrosis Factor-Receptor from lambdaTNF-R2 cDNA insert.
KW
     Tumour necrosis fa
                      pr binding protein; TNF-B
                                              TNF-receptor;
KW
     infectious disease; parasitic disease; cachexia;
```

autoimmune disease; shock; lambdaTNF-R2; raTNF-R8.

CC

KW

```
05
     Homo sapiens.
     EP-393438-A.
PN
PD
     24-DCT-1990.
     06-APR-1990; 106624
PF
     21-APR-1989; DE-913101.
PR
     21-JUN-1989; DE-920282.
PR
PA
     (BOEH ) BOEHRINGER INGELHEIMINT.
     Hauptmann R, Himmler A, Maurer-Fogy I, Stratowa C;
PΙ
     WPI; 90-321987/43.
DR
DR
     N-PSDB; Q06285.
PT
     DNA encoding TNF binding protein and TNF- receptor - used in
PT
     tumour treatment and to understand mechanismsm to TNF action
PS
     Disclosure; Fig 91(1-2); 51pp; German.
CC
     raTNF-R8 (\mathtt{Q06284}) was used to screen the \mathtt{HS913T} cDNA library.
CC
     CC
     construct a plasmid (pADTNF-R) expressing the product the
                                                          kamb√wau
CC
     as pADTNF-BP (see Q06282). The expressed proteins are puseful
     prophylactically and therapeutically to control disorders which
CC
     involve the damaging effects of TNF-alpha or -bet/a /e/g. infectious or
CC
CC
     parasitic diseases, shock, cachexia, autoimmune disgases, adult
CC
     respiratory distress syndrome etc., or side effects of treatment with
CC
     TNG-alpha). They can also be used as diagrafstic reagents for
CC
     assaying TNF and in study of TNF-receptor (interactions.
CC
     See also 006282-006285.
SQ
               455 AA;
     Sequence
SQ
     21 A; 27 R; 17 N; 21 D; 0
                             B; 30 C; 16 Q; 29 E; 0
                                                   Z; 29 G; 10 H;
50
     13 I; 57 L; 20 K; 5
                       M; 14 F; 37 P; 37 S; 30 T; 5
                                                   W; 13 Y; 24 V;
Initial Score
                   451
                        Optimized Score
                                            451
                                                Significance = 40.97
Residue Identitu
                   99%
                        Matches
                                            451
                                                Mismatches
                     0
                                                                  0
Gaps
                        Conservative Substitutions
                                                            ==
          10
                   20
                            30
                                     40
                                              50
                                                        60
                                                                 70
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   MGLSSVPDLLLPLVLVELLVGIYPSAVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   Х
          10
                   20
                            30
                                     40
                                               50
                                                        60
                                                                 70
         80
                  90
                          100
                                   110
                                            120
                                                     130
                                                              140
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
        80
                 90
                          100
                                   110
                                            120
                                                     130
                                                              140
      150
                        170
                                 180
                                          190
                                                   200
               160
                                                            210
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
   NCSLCLNGTVHLSC@EK@NTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLP@I@NVKGTEDSGTTVLLPL
      150
               160
                        170
                                 180
                                          190
                                                   200
                                                            210
    220
             230
                      240
                               250
                                        260
                                                 270
                                                          280
   VIFFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
   VIFFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
                                        260
    220
             230
                      240
                               250
                                                 270
                                                          280
                             320
  290
           300
                    310
                                      330
                                               340
                                                         350
                                                                  360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDTDDPATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
  290
           300
                    310
                             320
                                               340
                                                         350
                                                                  360
                                      330
                            390
                                                                430
         370
                  380
                                     400
                                              410
                                                       420
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
```

```
240
    220
             230
                                250
                                         260
                                                   270
                                                            280
   VIFFGLCLLSLLFIGLMYRY NKSKLYSIVCGKSTPEKEGELEGTT
                                                 LAPNPSFSPTPGFTPTLGFSPV
   VIFFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
    550
                       240
                                250
                                         260
                                                   270
                                                            280
  290
           300
                     310
                              320
                                        330
                                                 340
                                                          350
                                                                    360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDFATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
           300
                     310
                              320
                                        330
                                                 340
                                                          350
            Χ
                   380
   AVVENUPPLRWKEFURRLGLS
   AVVENVPPLRW
          370
6. US-07-625-668A-2 (1-455)
  R07450
              Rat Tumour Necrosis Factor-Receptor from raTNF-R8
ID
     R07450 standard; protein; 461 AA.
AC
     R07450;
DT
     29-JAN-1991
                 (first entry)
     Rat Tumour Necrosis Factor-Receptor from raTNF-R8 cDNA.
DE
KW
     Tumour necrosis factor binding protein; TNF-BP; TNF-receptor;
KW
     raTNF-R8.
os
     Rat rattus.
PN
     EP-393438-A.
PD
     24-OCT-1990.
     06-APR-1990; 106624.
PR
     21-APR-1989; DE-913101.
PR
     21-JUN-1989; DE-920282.
PA
     (BOEH ) BOEHRINGER INGELHEIMINT.
PΙ
     Hauptmann R, Himmler A, Maurer-Fogy I, Stratowa C;
DR
     WPI; 90-321987/43.
DR
     N-PSDB; Q06284.
     DNA encoding TNF binding protein and TNF- receptor - used in
PT
     tumour treatment and to understand mechanismsm to TNF action
PS
     Disclosure; Fig 8(1-2); 51pp; German.
CC
     A rat brain cDNA analogue of the HS913T cDNA library from rat
CC
     glioma cell line C6 (ATCC CCL107) is prepared in lambda-qt11.
CC
     The isolated clone raTNF-R8 is used as probe to isolated the entire
CC
     human TNF receptor, as represented in 006285.
CC
     See also 006282-006285.
50
               461 AA;
     Sequence
SQ
     22 A; 26 R; 20 N; 16 D; 0 B; 31 C; 16 Q; 25 E; 0
                                                    Z; 28 G; 14 H;
50
     16 I; 48 L; 20 K; 9
                        M; 17 F; 44 P; 31 S; 29 T; 5
                                                    W; 8
                                                         Y; 36 V;
Initial Score
                    240
                        Optimized Score
                                             212
                                                  Significance = 19.02
Residue Identity =
                    48%
                        Matches
                                             223
                                                  Mismatches
                                                                  232
Gaps
                      6
                         Conservative Substitutions
                                                                   0
                    20
                             30
                                       40
                                                50
                                                         60
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
       MGLPIVPGLLLSLVLLALLMGIHPSGVTGLVPSLGDREKRDNLCP@GKYAHPKNNSICCTKCHKGTYLVSDC,
   Х
           10
                    20
                             30
                                       40
                                                50
                                                         60
                                                                   70
                          100
                                    110
                                             120
                                                      130
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
                PSPG@ETVCELSHKGTFTAS@NHVR@CLSCKTCRKEMF@VEISPCKADMDTVCGCKKN@F@RYLSETHF@CV
```

PF

PT

80

90

100

110

120

130

```
390
          370
                   380
                                      400
                                               410
                                                         420
                                                                  430
                 450
        440
    CLEDIEEALCGPAALPPAPSLLR
    CLEDIEEALCGPAALPPAPSLLR
        440
                 450
5. US-07-625-668A-2 (1-455)
  R07449
               Tumour Necrosis Factor-Binding Protein from pTNF-B
     R07449 standard; protein; 371 AA.
     R07449;
     29-JAN-1991
                 (first entry)
     Tumour Necrosis Factor-Binding Protein from pTNF-BP15 cDNA.
     Tumour necrosis factor binding protein; TNF-BP; TNF-receptor;
     pTNF-BP15; infectious disease; parasitic disease; cachexia;
     autoimmune disease; shock.
     Homo sapiens.
     EP-393438-A.
     24-DCT-1990.
     06-APR-1990; 106624.
     21-APR-1989; DE-913101.
     21-JUN-1989; DE-920282.
     (BOEH ) BOEHRINGER INGELHEIMINT.
     Hauptmann R, Himmler A, Maurer-Fogy I, Stratowa C;
     WPI; 90-321987/43.
     N-PSDB; @06282.
     DNA encoding TNF binding protein and TNF- receptor - used in
     tumour treatment and to understand mechanismsm to TNF action
     Disclosure; Fig 1(1-3); 51pp; German.
     Clone pTNF-BP15 was used to contruct pADTNF-BP, for transfection of
     e.g. COS7 cells. The expressed proteins are useful
     prophylactically and therapeutically to control disorders which
     involve the damaging effects of TNF-alpha or -beta (e.g. infectious or
     parasitic diseases, shock, cachexia, autoimmune diseases, adult
     respiratory distress syndrome etc., or side effects of treatment with
                They can also be used as diagnostic reagents for
     assaying TNF and in study of TNF-receptor interactions.
     See also Q06282-Q06285.
     Sequence
               371 AA;
     13 A; 14 R; 16 N; 16 D; O B; 27 C; 13 Q; 21 E; O
                                                     Z; 25 G; 9
     11 I; 41 L; 19 K; 3
                        M; 13 F; 32 P; 33 S; 28 T; 4
                                                     W; 12 Y; 21 V;
Initial Score
                    371
                         Optimized Score
                                             371
                                                  Significance = 33.62
                   100%
Residue Identity =
                         Matches
                                             371
                                                  Mismatches
                                                              =
                                                                    0
Gaps
                      0
                         Conservative Substitutions
                                                                    0
                    20
                              30
                                       40
                                                50
                                                          60
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCP@GKYIHP@NNSICCTKCHKGTYLYNDC
    MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCP@GKYIHP@NNSICCTKCHKGTYLYNDC
           10
                    20
                              30
                                       40
                                                50
                                                          60
         80
                  90
                           100
                                    110
                                              120
                                                       130
   PGPG@DTDCRECESGSFTASENHLRHCLSCSKCRKEMG@VEISSCTVDRDTVCGCRKN@YRHYWSENLF@CF
    PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
         80
                  90
                           100
                                    110
                                              120
                                                       130
                                                                140
                160
                         170
                                  180
                                            190
                                                     200
   NCSLCLNGTVHLSC@EK@NTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLP@IENVKGTEDSGTTVLLPL
    NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
      150
```

ID

AC

DT

DE

KW

KW

KW

05

PN

PD

PF

PR

PR

PA

PI

DR

DR

PT PT

PS CC

CC

CC

CC

CC

CC

CC

CC

CC

SQ

SQ

SQ

160

170

180

190

200

| S | - | | | | * * | | | | | | |
|--------|------------|----|----|----|-----|----------|----------|----|----------|-----|-------|
| Ε | 50- | | | | | | | | | | |
| Q. | | | | | 4 | k | | | | | |
| U | - | | | | | | | | | | |
| Ε | - ₩ | | | | | | | | | | |
| N | - | | | | | ** | | | | | 2. |
| С | - | | | | | | | | | | • |
| E S | - | | | | | | | | | | |
| S | 10- | | | | | | | | | | * |
| | - | | | | | | | | | | |
| | - | | | | | | | | | | |
| | 5- | | | | | ** | | | | | |
| | - | | | | | | | | | | |
| | - | | | | | | | | | | |
| | - | | | | | | * | | | | |
| | - | | | | | | | | | | |
| | - | | | | | | | | | | |
| | | | | | | | | | * | | |
| | 0 | | | | | | | | | | · |
| | | į | İ | 1 | 1 | | <u>i</u> | ļ | <u> </u> | | |
| 510 |)EV-1 | 0 | 1 | 2 | 3 | 4 | 5 | | 7 | 8 . | |
| SCL | RE 4 | 13 | 22 | 31 | 40 | 49 | 58 | 67 | 76 | 84 | * * * |

PARAMETERS

| Similarity matrix Mismatch penalty Gap penalty Gap size penalty Cutoff score Randomization group | Unitary 5.00 0.26 0 | K-tuple Joining penalty Window size | 2 20 13 |
|---|------------------------------|---|---------------|
| Initial scores to save Optimized scores to sav | 20 | Alignments to save Display context | 1 O 1 O |

SEARCH STATISTICS

| Scores: | Mean | Median | Standard Deviation |
|---------|--------------------|--------|------------------------------|
| | 13 | 25 | 9.09 |
| Times: | CPU 00:02:47.05 | | Total Elapsed 00:05:40.00 |

Number of residues: 1849227 Number of sequences optimized: 4342

The scores below are sorted by optimized score. Significance is calculated based on optimized score.

4 100% identical sequences to the query sequence were found:

| Sequence Name | Description | Length | Init. Score | • | Sig. Frame |
|---------------|-------------------------------|--------|----------------|-----|------------|
| 1. A34899 | *Tumor necrosis factor recept | 455 | 455 | 455 | 48.61 0 |
| 2. A34900 | *Tumor necrosis factor recept | 455 | 455 | 455 | 48.61 0 |
| 3. S12057 | *Tumor necrosis factor recept | 4.55 | 455 | 455 | 48.61 0 |
| 4. A36555 | *Tumor necrosis factor recept | 455 | 455 | 455 | 48.61 0 |

The list of other best scores is:

| | | | Init. | Opt. | | |
|---------------|-------------|--------|-------|-------|------|-------|
| Sequence Name | Description | Length | Score | Score | Sig. | Frame |
| | | | | | | |

Number of scores above cutoff:

4342

Cut-off raised to 4. Cut-off raised to 5. Cut-off raised to 6. Cut-off raised to 7.

The scores below are sorted by initial score.
Significance is calculated based on initial score.

4 100% identical sequences to the query sequence were found;

| Sequence Name | Description | | Init. Opt. Score Score | Sig. Frame |
|---------------|-----------------------------|--------|---------------------------|------------|
| 1. A34899 | *Tumor necrosis factor rece | ot 455 | 455 455 | 97.80 0 |
| 2. A34900 | *Tumor necrosis factor rece | ot 455 | 455 455 | 97.80 0 |
| 3. 512057 | *Tumor necrosis factor rece | ot 455 | 455 455 | 97.80 0 |
| 4. A36555 | *Tumor necrosis factor rece | ot 455 | 455 455 | 97.80 0 |

The list of other best scores is:

| | | Init | . Opt. | | |
|---------------|------------------------------|--------------|------------|-------|-------|
| Sequence Name | Description | Length Scor | e Score | Sig. | Frame |
| | **** 97 standard deviations | above mean * | *** | | |
| 5. A38281 | *Tumor necrosis factor recep | t 455 45 | 2 452 | 97.15 | 0 |
| | **** 51 standard deviations | | * * * | | |
| 6. B36555 | *Tumor necrosis factor recep | | | 51.83 | 0 |
| | **** 47 standard deviations | | | | |
| 7. B40254 | *Tumor necrosis factor recep | | | 47.71 | 0 |
| 8. A38634 | *Tumor necrosis factor recep | | | 47.71 | |
| 9. 516677 | *P55 tumor necrosis factor r | e 454 22 | 4 267 | 47.71 | 0 |
| | **** 11 standard deviations | above mean * | *** | | |
| 10. C36555 | *Tumor necrosis factor bindi | | | 11.06 | 0 |
| | **** 3 standard deviations | above mean * | *** | | |
| 11. A38258 | *Tumor necrosis factor block | i 20 20 | 20 | 3.47 | 0 |
| | **** 1 standard deviation | | * * | | |
| 12. A42502 | *C22L protein - Vaccinia vir | | | 1.52 | 0 |
| 13. 142528 | *B28R protein - Vaccinia vir | | l 21 | 1.52 | |
| 14. W5WL11 | E5A protein - Human papillom | | 16 | 1.30 | |
| 15. S00897 | Pancreatic ribonuclease A pr | | 24 | 1.30 | 0 |
| 16. A31556 | Glucose-transporter protein, | | | 1.30 | 0 |
| 17. 505319 | Glucose transport protein, h | | | 1.30 | 0 |
| 18. S06920 | Glucose transport protein, h | e 523 10 | 28 | 1.30 | 0 |
| 19. S01085 | Hypothetical protein 1 - Whi | |) 43 | 1.30 | |
| 20. A35186 | *Salivary agglutinin recepto | r 1473 1 | 39 | 1.30 | 0 |

Query sequence being compared:US-07-625-668A-2 (1-455) Number of sequences optimized: 4342

Results of the optimized comparison of US-07-625-668A-2 (1-455) with: Data bank : PIR 32, all entries

```
7 standard deviations abol
                                                    mean ****
   6. S16677
                                                   454
                  *P55 tumor necrosis factor re
                                                                   27.93
                                                        224
                                                              267
   7. B40254
                  *Tumor necrosis factor recept
                                                  454
                                                        224
                                                              267
                                                                   27.93
   8. A38634
                  *Tumor necrosis factor recept
                                                   454
                                                        224
                                                              267
                                                                   27.93
                   **** 22 standard deviations above mean ****
   9. B36555
                  *Tumor necrosis factor recept
                                                        243
                                                   461
                                                              215
                                                                   22.21
                         7 standard deviations above mean ****
  10. C36555
                  *Tumor necrosis factor bindin
                                                   134
                                                               78
                                                                    7.15
                         4 standard deviations above mean ****
  11. B38634
                  *Tumor necrosis factor recept
                                                   474
                                                          8
                                                               55
                                                                    4.62
  12. A40254
                  *Tumor necrosis factor recept
                                                   474
                                                          8
                                                               55
                                                                    4.62
                         3 standard deviations above mean ****
  13. 518984
                  *Arrestin - Human (fragment)
                                                          8
                                                               49
                                                                    3.96
                                                   409
  14. GQHUN
                  Nerve growth factor receptor
                                                          9
                                                  427
                                                               49
                                                                    3.96
  15. OYB077
                  Guanylate cyclase, soluble, 7
                                                  691
                                                          6
                                                               49
                                                                    3.96
  16. S15921
                  *Protein TPX-VT3 - Thermoprot
                                                  474
                                                          8
                                                               49
                                                                    3.96
  17. B24785
                  Hupothetical protein 1028 - S
                                                  1028
                                                          6
                                                               48
                                                                    3.85
  18. A26728
                                                  747
                                                          7
                                                               48
                                                                    3.85
                  Elastin a precursor - Bovine
                                                                           0
                                                          7
  19. A36226
                  *Collagen alpha-1 - Sea urchi
                                                  730
                                                               48
                                                                    3.85
  20. A26456
                  Nicotinic acetylcholine recep
                                                  625
                                                          7
                                                               48
                                                                    3.85
1. US-07-625-668A-2 (1-455)
   A34899
               *Tumor necrosis factor receptor precursor, 55K 7
 ENTRY
                A34899
                           #Tupe Protein
 TITLE
                *Tumor necrosis factor receptor precursor, 55K -
                  Human
                01-Aug-1990 #Sequence 01-Aug-1990 #Text 01-Aug-1990
 DATE
 PLACEMENT
                          0.0
                                        0.0
                   0.0
                                 0.0
                                              0.0
 COMMENT
                *This entry is not verified.
 REFERENCE
                Loetscher H., Pan Y.C.E., Lahm H.W., Gentz R.,
    #Authors
                  Brockhaus M., Tabuchi H., Lesslauer W.
                Cell (1990) 61:351-359
    #Journal
    #Title
                Molecular cloning and expression of the human 55 kd
                  tumor necrosis factor receptor.
    #Reference-number A34899
    #Accession
                A34899
 SUMMARY
              *Molecular-weight 50494
                                       #Length 455
                                                   *Checksum
 SEQUENCE
Initial Score
                     455
                          Optimized Score
                                                455
                                                    Significance
                                                                   48.61
                                                                 =
Residue Identity
                    100%
                          Matches
                                                455
                                                    Mismatches
Gaps
                                                                       0
                       0
                          Conservative Substitutions
                     20
           10
                               30
                                         40
                                                  50
                                                            60
                                                                      70
    MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
    MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
    X
                     20
           10
                               30
                                         40
                                                  50
                                                            60
                                                                      70
         80
                   90
                            100
                                                120
                                      110
                                                         130
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
    PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
         80
                   90
                            100
                                                                   140
                                      110
                                                120
                                                         130
      150
                160
                          170
                                    180
                                              190
                                                       200
                                                                 210
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
    NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
```

**** 48 standard deviations above mean ****

455

452

48.28

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

*Tumor_necrosis factor recept

5. A38281

150

160

170

180

190

200

```
250
                                      260
                                               270
                                                        280
   VIFFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
   VIFFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
    220
             230
                     240
                              250
                                      260
                                               270
  290
           300
                   310
                            320
                                     330
                                             340
                                                      350
                                                              360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDTDDPATLY
  290
           300
                                             340
                   310
                            320
                                     330
                                                      350
                                                              360
         370
                  380
                          390
                                   400
                                           410
                                                    420
                                                             430
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
         370
                  380
                          390
                                   400
                                           410
                                                    420
                                                             430
       440
                450
                      X
   CLEDIEEALCGPAALPPAPSLLR
   CLEDIEEALCGPAALPPAPSLLR
       440
                450
2. US-07-625-668A-2 (1-455)
             *Tumor necrosis factor receptor precursor - Human ?
  A34900
ENTRY
              A34900
                        #Type Protein
TITLE
              *Tumor necrosis factor receptor precursor - Human
DATE
              01-Aug-1990 #Sequence 01-Aug-1990 #Text 01-Aug-1990
                             0.0
PLACEMENT
                       0.0
                                   0.0
                                         0.0
COMMENT
              *This entry is not verified.
REFERENCE
   #Authors
              Schall T.J., Lewis M., Koller K.J., Lee A., Rice
                G.C., Wong G.H.W., Gatanaga T., Granger G.A.,
                Lentz R., Raab H., Kohr W.J., Goeddel D.V.
   #Journal
              Cell (1990) 61:361-370
   #Title
              Molecular cloning and expression of a receptor for
                human tumor necrosis factor.
   #Reference-number A34900
              A34900
   #Accession
SUMMARY
            #Molecular-weight 50494
                                  #Length 455
                                             #Checksum
                                                        153
SEQUENCE
Initial Score
                  455
                       Optimized Score
                                          455
                                     ==
                                              Significance =
                                                           48.61
                  100%
Residue Identity =
                       Matches
                                          455
                                              Mismatches
                                                         =
                                                              0
Gaps
                    0
                       Conservative Substitutions
                                                              0
          10
                  20
                                    40
                           30
                                            50
                                                     60
                                                              70
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCP@GKYIHP@NNSICCTKCHKGTYLYNDC
   X
          10
                  20
                           30
                                    40
                                            50
                                                     60
        80
                 90
                         100
                                 110
                                          120
                                                  130
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
        80
                 90
                         100
                                 110
                                          120
                                                  130
                                                           140
              160
                       170
                               180
                                        190
                                                 200
                                                         210
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
                       NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
```

150

160

170

180

190

200

210

```
220
            230
                     240
                              250
                                      260
                                               270
   VIFFGLCLLSLLFIGLMYRY
                     WKSKLYSIVCGKSTPEKEGELEGTT
                                              LAPNPSFSPTPGFTPTLGFSPV
   VIFFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
    220
            230
                     240
                              250
                                      260
                                               270
                                                       280
  290
           300
                   310
                            320
                                             340
                                                      350
                                     330
                                                              360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
  290
           300
                   310
                            320
                                    330
                                             340
                                                      350
         370
                 380
                          390
                                   400
                                           410
                                                    420
                                                             430
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
         370
                 380
                          390
                                   400
                                           410
                                                    420
                                                             430
       440
                450
                      Х
   CLEDIEEALCGPAALPPAPSLLR
   CLEDIEEALCGPAALPPAPSLLR
       440
                450
                      X
3. US-07-625-668A-2 (1-455)
             *Tumor necrosis factor receptor type 1 - Human?
ENTRY
                        #Tupe Protein
TITLE
              *Tumor necrosis factor receptor type 1 - Human
DATE
              PLACEMENT
                       0.0
                             0.0
                                   0.0
                                         0.0
COMMENT
              *This entry is not verified.
SOURCE
              Homo sapiens #Common-name man
REFERENCE
   #Authors
              Nophar Y., Kemper O., Brakebusch C., Engelmann H.,
                Zwang R., Aderka D., Holtmann H., Wallach D.
              EMBO J. (1990) 9:3269-3278
   #Journal
              Soluble forms of tumor necrosis factor receptors
   #Title
                (TNF-Rs). The cDNA for the type I TNF-R, cloned
                using amino acid sequence data of its soluble
                form, encodes both the cell surface and a soluble
                form of the receptor.
   #Reference-number S12057
   #Accession
              S12057
SUMMARY
            #Molecular-weight 50494
                                 #Length 455
                                             #Checksum
                                                       153
SEQUENCE
                  455
Initial Score
                       Optimized Score
                                          455
                                     =
                                              Significance = 48.61
                  100%
Residue Identity =
                       Matches
                                          455
                                              Mismatches
                                                         =
                                                              0
Gaps
                    0
                       Conservative Substitutions
                                                              0
                  20
          10
                           30
                                    40
                                            50
                                                     60
                                                              70
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   X
          10
                  20
                           30
                                    40
                                            50
                                                     60
                                                             70
                                 110
        80
                 90
                         100
                                          120
                                                  130
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
        80
                 90
                         100
                                 110
                                          120
                                                           140
                                                  130
```

160

170

180

190

200

```
NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
                                         190
      150
               160
                        170
                                180
                                                  200
    220
             230
                      240
                               250
                                       260
                                                270
   VIFFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
   VIFFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
             230
                      240
                               250
                                       260
                                                270
                                                         280
  290
           300
                    310
                             320
                                                       350
                                      330
                                              340
                                                                360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
  290
           300
                    310
                             320
                                      330
                                              340
                                                       350
                                                                360
         370
                  380
                           390
                                    400
                                                      420
                                                              430
                                             410
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
         370
                  380
                           390
                                    400
                                                      420
                                             410
                                                              430
        440
                450
                       X
   CLEDIEEALCGPAALPPAPSLLR
   CLEDIEEALCGPAALPPAPSLLR
        440
                450
4. US-07-625-668A-2 (1-455)
  A36555
              *Tumor necrosis factor receptor precursor - Human /
 ENTRY
               A36555
                        #Type Protein
 TITLE
               *Tumor necrosis factor receptor precursor - Human
 DATE
               15-Apr-1991 #Sequence 15-Apr-1991 #Text 15-Apr-1991
 PLACEMENT
                       0.0
                              0.0
                                    0.0
 COMMENT
               *This entry is not verified.
 SOURCE
               Homo sapiens #Common-name man
 REFERENCE
   #Authors
               Himmler A., Maurer-Fogy I., Kroenke M., Scheurich
                P., Pfizenmaier K., Lantz M., Olsson I., Hauptmann
                R., Stratowa C., Adolf G.R.
   #Journal
               DNA Cell Biol. (1990) 9:705-715
   #Title
               Molecular cloning and expression of human and rat
                tumor necrosis factor receptor chain (p60) and its
                soluble derivative, tumor necrosis factor-binding
                protein.
   #Reference-number A36555
   #Accession
               A36555
 SUMMARY
             #Molecular-weight 50494
                                   #Length 455
                                              #Checksum
                                                         153
 SEQUENCE
Initial Score
                   455
                       Optimized Score
                                           455
                                               Significance = 48.61
                                               Mismatches
Residue Identity =
                  100%
                       Matches
                                           455
                                                           =
                                                                0
Gaps
                     0
                       Conservative Substitutions
                                                                0
                   20
                            30
                                     40
                                              50
                                                      60
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDC
   Х
          10
                   20
                            30
                                     40
                                              50
                                                      60
                                                               70
                 90
                         100
                                  110
                                           12(
                                                    130
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
```



```
80
                 90
                         100
                                  110
                                           120
                                                    130
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
   PGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
                 90
                         100
                                  110
                                           120
                                                    130
      150
               160
                        170
                                 180
                                         190
                                                  200
                                                           210
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
   NCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPL
      150
               160
                        170
                                 180
                                         190
                                                           210
                                                  200
    220
             230
                      240
                               250
                                                270
                                        260
                                                         280
   VIFFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
   VIFFGLCLLSLLFIGLMYRY@RWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPV
    220
                      240
                               250
                                        260
                                                270
  290
           300
                    310
                             320
                                      330
                                               340
                                                        350
                                                                360
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
   PSSTFTSSSTYTPGDCPNFAAPRREVAPPY@GADPILATALASDPIPNPL@KWEDSAHKP@SLDTDDPATLY
  290
           300
                    310
                             320
                                      330
                                               340
                                                        350
                                                                360
         370
                  380
                           390
                                    400
                                                      420
                                             410
                                                               430
   AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLG
             AVVENVPPLRTLEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRNMDLLG
         370
                  380
                           390
                                    400
                                             410
                                                      420
                                                               430
                450
        440
                       X
   CLEDIEEALCGPAALPPAPSLLR
   CLEDIEEALCGPAALPPAPSLLR
        440
                450
6. US-07-625-668A-2 (1-455)
  S16677
              *P55 tumor necrosis factor receptor - Mouse
 ENTRY
                        #Tupe Protein
 TITLE
               *P55 tumor necrosis factor receptor - Mouse
 DATE
               07-Apr-1992 #Sequence 07-Apr-1992 #Text 07-Apr-1992
 PLACEMENT
                       0.0
                              0.0
                                    0.0
                                          0.0
 COMMENT
               *This entry is not verified.
 SOURCE
               Mus musculus #Common-name house mouse:
 REFERENCE
   #Authors
               Barrett K., Taylor-Fishwick D.A., Cope A.P.,
                Kissonerghis A.M., Gray P.W., Feldmann M., Foxwell
                B.M.J.
   #Journal
               Eur. J. Immunol. (1991) 21:1649-1656
   #Title
               Cloning, expression and cross-linking analysis of
                the murine p55 tumor necrosis factor receptor.
   #Reference-number S16677
   #Accession
               S16677
   #Cross-reference EMBL: X59238
 SUMMARY
             #Molecular-weight 50129 #Length 454
                                               #Checksum
                                                        4839
 SEQUENCE
                   224
Initial Score
                       Optimized Score
                                           267
                                               Significance = 27.93
Residue Identity
                   62%
                       Matches
                                           287
                                       =
                                               Mismatches
                                                           =
                                                               164
              =
Gaps
                     6
                        Conservative Substitutions
                                                                0
                   20
                            30
                                     40
                                                       60
   MGLSTVPDLLLPLVLLELLV YPSGVIGLVPHLGDREKRDSVCP@GKY1HP@NNSICCTKCHKGTYLYNDC
```